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Abstract 
 
 
  “Head-to-head” terpene synthases catalyze the first committed steps in sterol and 
carotenoid biosynthesis: the condensation of two isoprenoid diphosphates to form 
cyclopropylcarbinyl diphosphates, followed by ring opening.  In this work, I used x-ray 
crystallography, and mutagenesis to study the catalytic mechanism of Staphylococcus 
aureus dehydrosqualene synthase.  Dehydrosqualene synthase (CrtM) is also the first 
committed enzyme in the biosynthesis of staphyloxanthin, a carotenoid pigment, and a 
major virulence factor in S. aureus.  Inhibitors targeting CrtM and staphyloxanthin 
biosynthesis are therefore of interest as “anti-virulence” based therapy for treating S. 
aureus infection.  I studied the structure-activity-relationship of phosphonosulfonate and 
phosphonoacetamide compounds in CrtM inhibition, and I also developed a series of non-
phosphonate CrtM inhibitors using rational- and structure-based approaches. 
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Chapter 1 
Drug Discovery Targeting Isoprenoid Biosynthesis 
Enzymes 
 
1.1 Isoprenoid Biosynthesis  
Terpenes (or isoprenoids) are the largest class of nature products on earth [1], and some of the 
enzymes involved in the isoprenoid biosynthesis pathway are targets of widely prescribed drugs.  
For example, bisphosphonates, such as Fosamax, used to treat bone resorption diseases, target 
the enzyme farneysl diphosphate synthase (FPPS) in the pathway, while antifungals such as 
terbinafine target the sterol biosynthesis.  The basic building blocks of isoprenoid are the C5 
isopentenyl diphosphate (1, IPP) and dimethylallyl diphosphate (2, DMAPP), Scheme 1.1.  
Farnesyl diphosphate synthase (FPPS) catalyzes the condensation of IPP and DMAPP, using a 
“head-to-tail” mechanism, to form geranyl 
diphosphate (GPP) and farnesyl diphosphate (FPP, 4), 
and further reaction with IPP catalyzed by the enzyme 
geranylgeranyl diphosphate synthase (GGPPS) yields the C20 species, geranylgeranyl 
diphosphate (GGPP, 5), Scheme 1.2. 
 
Scheme 1.1 
 
       2             1                   GPP (C10), 3             FPP (C15), 4                         GGPP (C20), 5      
Scheme 1.2 
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Both FPP and GGPP are used in protein prenylation, which is important for cell survival and 
signaling pathways, and two molecules of C15 FPP can also condense in a “head-to-head” 
fashion, through a presqualene diphosphate intermediate (PSPP, 6) [2] to form triterpenes 
(Scheme 1.3). In humans, this reaction is couple with an NADPH reduction step and results in 
formation of squalene [3], 7, but in S. aureus, and few other bacteria, the reduction step is absent, 
so the product of condensation reaction is dehydrosqualene [4], 8.  In eukaryotes, squalene is 
epoxidized to form oxidosqualene, 9, which is then cyclized to form lanosterol, 10, which after 
several additional steps, is transformed into cholesterol, 11, in humans or ergosterol, 12, or 
 
Scheme 1.3 
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episterol, 13, in yeasts, fungi, and parasitic protozoa. In S. aureus, 8 will be further converted to 
a carotenoid pigment, staphyloxanthin [4], 14, an important virulence factor. The enzymes 
involved in these reactions are the targets (Figure 1.1) of interest in our lab, but this work is 
focused on the enzymes that catalyze the head-to-head condensations, i.e. the triterpene 
synthases.  In  Chapter 2, I discussed the mechanistic studies on the dehydrosqualene synthase 
from S. aureus.  
 
1.2 Targeting Staphyloxanthin Biosynthesis 
 
Staphylococcus aureus infection is a major threat to public health.  As pointed out in the recent 
studies [5, 6], S. aureus infections are now responsible for more deaths in the US than are caused 
by HIV/AIDs. Despite the prevalence of hospital and community acquired infections from drug-
resistant strains have increased steadily, the number of FDA approved antibacterials has actually 
decreased (Figure 1.2, adopted from ref [7]). Only two new antibiotics with novel mode of action 
have been introduced since 1990. The National Academies of Science/National Research 
Council recently published the results of two Workshops on the Development of Novel 
Antimicrobial Therapeutics [8] noted: “An anti-infective agent that does not kill is less likely to 
select for drug resistance as the selection pressure is less intense.” Targeting bacterial virulence 
factors was discussed as a new way of alleviating the drug-resistance problem.  
          A major virulence factor in S. aureus is a glycosylated carotenoid pigment, 
staphyloxanthin [4], which is responsible for the golden color of the bacterium. Like β-carotene, 
staphyloxanthin acts as an anti-oxidant using its numerous double bonds to quench the reactive 
oxygen species (ROS, like OH, H2O2) from host neutrophils, thus S. aureus can evade from 
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innate immune killing.  Blocking staphyloxanthin biosynthesis is thus a target for therapeutic 
intervention [9]. 
          As noted in the previous section, the first committed step in staphyloxanthin biosynthesis 
is catalyzed by the enzyme dehydrosqualene synthase (CrtM), which condenses two C15 farnesyl 
diphosphate molecules to make dehydrosqualene, which then converted by the downstream 
enzymes [4] to form the bright orange pigment staphyloxanthin, Figure 1.3A. Liu et al has 
shown that a S. aureus CrtM knockout [9] is not pigmented, and in a mouse model, did not cause 
any infection (Figure 1.3B), since it was highly susceptible to ROS-induced killing.  In 
eukaryotes, a critical enzyme in de novo cholesterol and ergosterol biosynthesis, squalene 
synthase (SQS), catalyzes a similar condensation reaction of two FPP molecules. In CrtM, PSPP 
is converted to dehydrosqualene, while in SQS, additional reduction by NADPH makes squalene 
the enzyme’s final product (Figure 1.3A).  Since two enzymes use identical substrate and 
catalyze very similar reactions, we reasoned that known inhibitors of human squalene synthase 
(SQS), which previously developed as cholesterol-lowering drugs, might also act against 
dehydrosqualene synthase.   
 
 
1.3   Repurposing Human Squalene Synthase Inhibitors 
         SQS inhibitors have been developed extensively by Bristol-Myers Squibb, Zeneca, Rhone-
Poulenc, Eisai, Pfizer and Takeda Pharmaceuticals as anti-hyperlipidemia drugs (since they 
block formation of the squalene used to produce cholesterol), and there is an extensive body of 
animal and human testing on such inhibitors.  Our group made a series of known SQS inhibitors 
and tested them for their ability to inhibit pigment formation in S. aureus.  The most active 
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inhibitor of the compounds initially studied was BPH-652, a phosphonosulfonate developed by 
BMS [10]. BPH-652 showed an IC50 of 120 nM in pigment formation, in bacterial cell based 
assay, it caused the same effect as the CrtM knockout, while it has no 
observable effects on cell growth but pigment formation was blocked.  
By blocking the staphyloxanthin biosynthesis, treatment of BPH-652 
made S. aureus more susceptible to hydrogen peroxide killing [11] (Figure 1.4A), enhanced the 
efficacy of whole blood killing, Figure 1.4B, and greatly reduced S. aureus proliferation in an i.p. 
model of infection, Figure 1.4C.  These results clearly demonstrated the feasibility of anti-
virulence based therapy: blocking staphyloxanthin pigment (virulence factor) formation (in cells) 
by CrtM inhibitors indeed reduced bacterial CFU in mice by enhancing neutrophil-baed killing 
and thus increased mice survival rate. To optimize the potency and selectivity of BPH-652, our 
group has synthesized series of analogs and I will discuss the structure-activity relationship 
(SAR) studies of these compounds in Chapter 3 and Chapter 4. 
 
1.4   Identifying Novel Dehydrosqualene Synthase Inhibitors  
         Lipophilic bisphosphonate SQS inhibitors were first developed by BMS in early 1990s as 
cholesterol-lowering agents [12]. Bisphosphonates (like FBP [11], Scheme 1.4) are very potent 
against SQS enzyme (IC50 ~1 nM) and effective in animal models. However, further 
development was discontinued because these sorts of compounds have very low oral availability, 
high bone binding affinity and high liver toxicity. It was proposed that the undesired tissue 
retention and low absorption were due to the highly charged nature of bisphosphonate head 
group (tetraacid), which make traversing cellular membrane very difficult [13]. To alleviate these 
issues, BMS later developed phosphonosulfonates (triacid) compounds (i.e. BPH-652), but BPH-
O
SO3K
P(O)(K)2
BPH-652  
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652 is still highly charged, so a bis(pivaloyloxy)methyl ester prodrug (BMS-188494) was used to 
overcome the absorption issue.  BMS-188494 finally entered clinical trial. To avoid similar 
problems of BPH-652, Takeda and Pfizer have developed benzo-xazepine compounds carrying a 
singly charged carboxylic acid, TAK-475 [14], Scheme 1.4.  The evolution of synthetic SQS 
inhibitors showed a clear trend: reducing charge and increasing hydrophobic substituents, i.e. 
higher LogP (octanol-water partition coefficient).  More lipophilic groups are necessary to 
compensate the reduction in the ionic interactions contributed from the phosphonate or sulfonate 
groups.  Synthetic small molecules with higher logP values are more likely to be membrane 
permeable in both mammalian and bacterial system as showed in several studies by our group 
using combinatorial descriptor search approach [15].  Following this rationale, we reasoned that 
non-phosphonate, lipophilic CrtM inhibitors could be developed into orally available anti-
virulence agents for treating S. aureus infections.  Unfortunately, enzyme screening results 
showed that all reported non-phosphonate SQS inhibitors showed no or very little activity 
against CrtM, in enzyme or cell.  In the final Chapter, I adopted structure-based virtual screening 
and rational design methods to identify novel drug-like CrtM inhibitors. Some compounds have 
shown potent enzyme and virulence inhibition in S. aureus.  Crystal structures of CrtM-inhibitor 
 
Scheme1.4 Evolution of substrate analog based squalene synthase inhibitors: from bisphosphonate to 
phosphonosulfonate to di-carboxylic acid and finally carboxylic acid. The hydrophobic substituents got 
bigger so that the reduced ionic interaction can be compensated by hydrophobic interaction. 
 
Farnesyl-  
Bisphosphonate 
(FBP) 
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complex were determined in order to optimize these leads.  Mouse studies on some lead 
compounds are currently being conducted by our collaborators in UCSD.  
 
 
1.5  Figures 
 
Figure 1.1 Drug targets and their inhibitors in the isoprenoid pathway 
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Figure 1.2 (A) The number of new systemic antibiotic agents has declined since 1980, and most 
(75%) of these drugs are in two classes, beta-lactams and quinolones (B) Timeline of antibiotic 
development and the evolution of antibiotic resistance. The year each antibiotic was deployed is 
depicted above the timeline, and the year resistance to each antibiotic was observed is depicted 
below the timeline. 
 
 
 
 
 
 
Figure 1.3 (A) Biosynthetic pathway of staphyloxanthin and cholesterol. Like SQS, CrtM first 
catalyzes the condensation of 2 FPP to presqualene diphosphate (PSPP), then PSPP was 
converted to dehydrosqualene in the 2nd half reaction. In SQS, joining of NADPH makes 
squalene its final product of 2nd half reaction. In S. aureus, dehydrosqualene will be further 
processed by the downstream enzymes (CrtN, O, P Q) to form the pigment, staphyloxanthin.  (B) 
CrtM knockout S. aureus is white and non-infective, so it won’t cause lesion in mice.   
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Figure 1.4 (A) H2O2 and (B) whole blood survival assay of S. aureus showing effects of BPH-
652.  (C) Colony-forming units recovered from kidney after the treatment of BPH-652. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
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Chapter 2 
Head-to-Head Terpene Synthases: Mechanism of 
Action 
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2.2 Introduction 
“Head-to-head” terpene synthases catalyze the first committed steps in the biosynthesis of sterols 
and carotenoid pigments: the C1′-2,3 condensation of two isoprenoid diphosphates to form a 
cyclopropylcarbinyl diphosphate (1, 2), followed by ring-opening to form squalene, 
dehydrosqualene or phytoene. In humans and in many pathogenic yeasts, fungi and protozoa, as 
well as in plants, the isoprenoid diphosphate is farnesyl diphosphate (FPP) and the initial product 
is the C30 isoprenoid, presqualene diphosphate (PSPP). As implied by its name, PSPP is then 
converted (by the same enzyme as used in the condensation reaction, squalene synthase, SQS) to 
squalene which, after epoxidation, is cyclized to lanosterol (3) as shown in Fig. 1. Lanosterol 
then undergoes numerous additional reactions, resulting in formation of sterols, key cell 
membrane components. As such, squalene synthase inhibitors are of interest as anti-parasitics, in 
particular against Trypanosoma cruzi (4) and Leishmania spp. (5), the causative agents of 
Chagas disease and the leishmaniases. In plants, the related enzyme phytoene synthase (PSY) 
catalyzes the condensation of two C20 isoprenoid diphosphate (geranylgeranyl diphosphate, 
GGPP) molecules (6) to form prephytoene diphosphate (PPPP) that, after ring opening, forms 
phytoene, which is then converted to carotenoid pigments (7) (Fig. 1). In the bacterium 
Staphylococcus aureus, the initial step in formation of the carotenoid pigment staphyloxanthin 
(STX) is carried out by condensation of two FPP molecules by the enzyme dehydrosqualene 
synthase (CrtM), again initially forming PSPP (8), which is then converted by the same enzyme 
to dehydrosqualene, which is further transformed to STX (8). Since STX is a so-called 
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“virulence factor” for S. aureus (9), inhibiting its formation is of interest in the context of 
developing new routes to anti-infective therapies (10). 
            Given the key role of the head-to-head tri- and tetra-terpene synthases in sterol and 
carotenoid biosynthesis, there has been remarkably little work reported on their three-
dimensional structures. There has been one report of the structure of human SQS with a bound 
inhibitor (11), but relatively little mechanistic information was obtained because the inhibitor 
was not obviously substrate, intermediate or product-like. In our group, we reported the x-ray 
crystallographic structure of CrtM from S. aureus, (10). There were two substrate-analog 
inhibitor binding sites (sites S1 and S2), but determining which represented the prenyl donor (the 
“allylic” FPP that ionizes to form the 1′ carbocation) and which represented the prenyl acceptor 
(that provides the C2,3 alkene group) was not attempted since the 1′-2,3 distances for both 
possible assignments were ~5Å. In this chapter, I reported new structural and mechanistic 
models for head-to-head terpene synthase activity, and inhibition, based on ten new x-ray 
structures; studies of site-directed mutagenesis based on both structure and bioinformatics; 
chemical reactivity; and comparisons with “head-to-tail” terpene synthases and terpene cyclases.  
 
2.3 Results and Discussion 
Structure of Presqualene Diphosphate (PSPP) Bound to Dehydrosqualene Synthase (CrtM) 
The overall reactions catalyzed by CrtM, SQS and phytoene synthase (PSY) are shown in Figure 
2.1A and involve ionization of one isoprenoid diphosphate molecule to form a 1′ carbocation, 
which then undergoes nucleophilic attack by the C2,3 double bond in the second isoprenoid 
diphosphate to form, after proton loss, presqualene diphosphate (PSPP) or prephytoene 
diphosphate (PPPP), Figure 2.1B. After a second ionization, these molecules then undergo a 
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complex series of rearrangements (12) thought to involve cyclopropyl and cyclobutyl species to 
form either primarily dehydrosqualene (with CrtM; or SQS in the absence of NADPH); squalene 
(with SQS, in the presence of NADPH), or phytoene (with PSY). But which site houses the 
cation (donor), and which is the alkene (acceptor)?  Where do the carbocations bind? How do 
PSPP and dehydrosqualene (DHS) bind to CrtM (or SQS)? And where do the diphosphates 
ionize? In previous work on CrtM (10) our group used the non-reactive substrate analog, S-
thiolo-farnesyl diphosphate (FSPP), to define two prenyl diphosphate binding sites: S1 and S2. 
The structure obtained (PDB ID code 2ZYP) is shown in Figure 2.2A from which it can be seen 
that the C1′-C2,3 distances for the 2 possible mechanistic models (i.e. S1=donor, or S1=acceptor) 
are very similar (5-5.4 Å) making it impossible to make reliable donor/acceptor site assignments 
based solely on this metric.  
We therefore produced a CrtM mutant (Y129A) that, based on sequence alignment with 
rat SQS, corresponds to Y171 in the rat protein, which is known to be un-reactive (13). The 
Y129A CrtM mutant was indeed un-reactive, with either FPP (0% activity) or PSPP (7% activity, 
Figure 2.3) as substrate, indicating that both the first half (PSPP formation) as well as the second 
half (PSPP to dehydrosqualene) reactions were inhibited, which enabled us to obtain diffraction 
quality crystals of a CrtM/PSPP complex. Our initial CrtM/PSPP crystals diffracted to 2.4 Å (full 
crystallographic data and structure refinement details are given in Table 2.1), and using the 
CrtM-FSPP structure (PDB ID code 2ZY1) minus ligands as a template, we obtained the electron 
density results shown in Fig. S2A (PDB ID code 3LGZ). We then obtained a second structure 
(electron density shown in Fig. 2B) with improved (1.89 Å) resolution at a higher [Mg2+] (PDB 
ID code 3ADZ; full crystallographic data and structure refinement details are given in Table 2.1), 
Figure 2.2C.  Both structures (which have a 0.3 Å protein Cα and 0.7 Å ligand rmsd) are shown 
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superimposed in Figure 2.4C.  In addition, we obtained a third PSPP structure using wild type 
CrtM (crystallized in the presence of 0.2M sodium tartrate (Figure 2.4B,D; Table 2.1) which had 
a 0.18Å, 0.45Å protein and 0.19Å, 0.8Å ligand rmsd versus the two mutant structures, indicating 
all three structures are virtually identical. 
What is immediately obvious from these structures, shown (in cyan) superimposed on the 
CrtM/FSPP structure (in green/yellow) in Figure 2.2C, is that: i) the PPi seen in the S1 FSPP site 
is no longer present, indicating that the FPP in this site is the prenyl donor (which ionizes to form 
the 1′-carbocation); ii) the S1 FPP C1′ moves down by ~ 2.5 Å to form C1′ in PSPP while iii), 
the S2 FPP C2 and C3 move up by ~ 1.5 Å, to form C2,3 in the cyclopropane ring of the PSPP 
product; iv) the S2 PPi group moves “up” somewhat (on average, the non-H atoms move by ~ 
1.8 Å), but overall this group remains very close to its original position and v) the lower ~2/3rds 
of the PSPP side-chains hardly move at all with respect to their positions in FSPP, only a ~ 1.2 Å 
rmsd for 27 carbon atoms (0.7 Å for 25 carbons). Also of interest is the observation that the 
PSPP side-chain in S1 is highly “bent” and, while it appears shorter, is actually the longer one 
(11 versus 9 contiguous carbons), while the S2 chain is quite straight, occupying the same site as 
the biphenyl ring-containing inhibitors reported previously (10).  These results strongly support a 
“first-half” reaction mechanism in which FPP in S1 ionizes to form the primary carbo-cation 
which then moves down to react with the C2,3 double bond in the FPP in S2 to form (after H+ 
abstraction), PSPP, with the highly conserved Asp residues in the first DXXXD domain being 
essential for catalysis, Figure 2.3.  To further test this mechanistic proposal, we next investigated 
the structure and activity of a series of S-thiolo-diphosphates interacting with CrtM. 
Structure and Activity of Substrate Analogs   In our previous work on CrtM, we used S-
thiolo-FSPP as an un-reactive substrate analog (10). The lack of activity of other S-thiolo-
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isoprenoid diphosphates as allylic/cationic prenyl donors has been studied extensively by Poulter 
et al. (14) who found that e.g. S-thiolo-DMAPP inhibits FPPS (since it does not ionize, in the 
allylic site, S1), while S-thiolo-IPP does inhibit FPPS, since it forms S-thiolo-GPP, which again 
cannot ionize, in S1 (14). Plus, Hosfield et al. (15) have shown that S-thiolo-DMAPP binds to 
the allylic (S1) site in FPPS, as does S-thiolo-FPP in GGPPS (16). This leads to the idea that 
other S-thiolo-isoprenoid diphosphates might be interesting probes of CrtM structure, and 
function. 
In order to see how FSPP might inhibit the conversion of FPP to PSPP, and thence 
dehydrosqualene, we carried out a series of CrtM inhibition experiments. Remarkably, we found 
that the rate of the CrtM reaction (monitored in this case via PPi release) increased with FSPP 
concentration, Figure 2.5A. When we assayed for DHS production, we found that its formation 
was being inhibited, Figure 2.5B, so it seemed that FSPP must be reacting with FPP to form a 
non-reactive S-thiolo-PSPP, in much the same way that S-thiolo-IPP can react with DMAPP in 
FPPS to form S-thiolo-GPP (14). To verify formation of S-thiolo-PSPP, we isolated the product 
of the reaction chromatographically, then carried out a reductive cleavage (17) and obtained the 
mass spectrometry results shown in Figure 2.6, which confirm formation of a C30H50S product, 
presqualene thiol. 
To investigate this topic in more detail, we next investigated the reactions between 
farnesyl and geranylgeranyl diphosphates and S-thiolo diphosphates (representative LC-MS 
results are shown in Figure 2.7, 2.8 and are summarized in Table 2.2.). The results can be 
summarized as follows: Only FPP (in the S1 site) can ionize, while FPP, GGPP, FSPP or GGSPP 
(in S2) can all provide the alkene, prenyl acceptor, in wt CrtM. So, longer chains (C20) can fit in 
S2, but not in S1, since we find no activity (PPi release) with GGPP as substrate. However, in an 
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F26A mutant, GGPP actually reacts to form phytoene (18), since the bulky F26 (at the “bottom” 
of the S1 binding site) which blocks GGPP binding to S1 is removed, and the reaction can 
proceed. If this idea is correct, it should be possible to bind two molecules of GGSPP to the 
F26A CrtM mutant. This is indeed the case, as shown in Figure 2.5C,D where we see that the S1 
side-chain in the CrtM/GGSPP complex (PDB ID code 3AE0; Table 2.1) would clash with F26, 
shown in red (if it were present). These results are all consistent with S1 being the ionization site 
for FPP in PSPP formation. 
A Catalytic Model for Dehydrosqualene Synthase  These results all support the initial reaction 
model shown in Fig. 4 in which the S1 FPP ionizes to form the 1′-carbocation, Figure 2.9A, B. 
This carbo-cation then moves down into the interior of the protein to react with C2,3 in the S2 
FPP, Figure 2.2D and Figure 2.9B, with remarkably little change in the conformation of the 
lower ~2/3rds of the FSPP/PSPP hydrocarbon chains (Figure 2.2C). The second PPi in PSPP then 
moves up (Figure 2.9C) into the S1 site to interact with the three Mg2+, and the 
cyclopropylcarbinyl cation so formed (Figure 2.9D,E) then rearranges, as proposed (12), forming 
DHS (Figure 2.9F), which we find binds to the surface pocket shown in Figure 2.10A,B (PDB ID 
code 3NRI; full crystallographic data and structure refinement details are given in Table 2.1). 
Chemical structures are shown for clarity in Figure 2.9G. The alternate model (Figure 2.9H) in 
which the S2 site FPP ionizes initially, results in the longer (11 contiguous carbons) PSPP side-
chain occupying the S2 product site, which is not seen experimentally.  
Catalytic Roles of the Enzyme  But which residues are involved in the second-half reaction?  
One possibility is that the PSPP diphosphate just ionizes in the S2 site and there is indeed one 
Mg2+ that interacts with the PSPP PPi group. The second possibility is that the PSPP diphosphate 
group could simply flip back up to the two DXXXD/Mg2+3 domains to undergo this second 
 19 
ionization, as illustrated in the Glide (26) docking pose shown in Figure 2.10C. To help 
distinguish between these two possibilities, we used the JPRED3 (19) and SCORECONS (20) 
programs to rank-order the essential residues in CrtM (excluding structural Gly, Ala, and Pro), 
then mutated 9 of these to Ala and tested their activity in both 1st half (FPP to PSPP) and second 
half (PSPP to DHS) reactions. Results are shown in Figure 2.3. What is clear from these results 
is that Y129 as well as all of the top ranked Asp residues (D48 and D52 in the first Asp-rich 
region; D172 and D176 in the second Asp-rich domain; Figure 2.10C) are essential for both 1st 
and 2nd half reactions. This strongly supports the ionization of both FPP as well as PSPP in the 
same site—the Mg2+3 tri-metal cluster observed in the FSPP structure (Figure 2.2A).  Although 
D52 and Y129 are essential for both half reactions, their roles in the catalysis are not obvious.  
When examining the substrate-, intermediate-, and the product-bound structures, Y129 is ~8Å 
from the closest ligand, and D52 of the 1st DDXXD loop, presumably involved in the ionization, 
is ~5Å away from the closest Mg2+ ion. It seems that the most likely role for these two highly 
conserved residues is to facilitate removal of the Mg2+/PPi leaving group formed in both half-
reactions, from the enzyme (Figure 2.1B).  However, trails of getting a complex structure of 
CrtM with PPi/Mg2+ alone were not successful.  We later confirmed (in the following section) 
the binding site of PPi leaving group by solving a ternary complex structure of CrtM, PPi/Mg2+, 
plus a cationic inhibitor, BPH-651 
(Scheme 2.1). 
 
Cationic SQS/CrtM Inhibitors and 
Carbocation Transition States  Next, 
we consider CrtM and SQS inhibition. 
 
Scheme 2.1 
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One of the most potent classes of SQS inhibitor are the quinuclidines (or quinuclidinols), 
compounds such as BPH-651, and E5700 and ER119884 (from Eisai Pharmaceuticals), which 
have been found to have low nM activity against both T. cruzi and human SQS (4, 5, 21), as well 
as potent activity against T. cruzi cell growth (5). These compounds are of interest as novel anti-
infectives, but nothing is known structurally about how they might act. The 3-OH quinuclidine 
pKa is expected to be  ~10-11 (22), so these compounds are likely to bind to SQS as cationic 
(ammonium) species, and it seemed possible that, as with e.g. nitrogen-containing 
bisphosphonate inhibitors of FPPS (23, 24), they might mimic the transition state/reactive 
intermediates involved in PSPP (or squalene/dehydrosqualene) formation. Although BPH-651 is 
only a modest CrtM inhibitor (Ki= 17.5 µM), we were able to obtain a complex structure of 
BPH-651/CrtM (full crystallographic details are given in the Table 2.3), as well as that of a 
second ammonium-containing species (25) BPH-673 (Table 2.3), a potent SQS inhibitor which 
has a Ki ~2 µM for CrtM inhibition, both complex structures were obtained by soaking. Both 
compounds contain biphenyl side-chains and bind into the “linear” S2 site, as shown in Figure 
2.11A,B. In each case, the positively charged center (blue) is located quite near the cyclopropyl 
ring in PSPP (BPH-651, 1Å closest distance; BPH-673, 2Å), with the superpositions shown in 
Figure 2.11A,B clearly suggesting that both cationic inhibitors act as transition state/reactive 
intermediate analogs which occupy the S2 site, mimicking a cyclopropyl carbocation species 
(transition state 2 in Figure 2.2B), rather than being isosteres for the farnesyl carbocation which 
forms in S1. In FPPS, the cationic or nitrogen-containing bisphosphonate class of inhibitors bind 
to the S1 site (18,20,21), but of course most of the binding energy there can be attributed to the 
bisphosphonate/Mg2+3 interaction.  Nevertheless, S1-site carbocation, in principle, must exist 
based on the enzyme catalytic mechanism (Figure 2.2B), and our results that FPP as well as 
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PSPP ionize (to yield carbocation) in S1 site.  So, we seek other ways of getting the complex 
structures. It was reported that the inhibition of SQS by quinuclidine compounds can be 
enhanced by co-incubating with inorganic diphosphate (5). This observation suggested the 
presence of an SQS-quinuclidine-PPi ternary complex.  We therefore tested this hypothesis in 
CrtM, and a clear electron density of the PPi group (Figure 2.12A) was observable only when co-
crystallizing with BPH-651 and excess amount of Mg2+.  Figure 2.12B showed the superposition 
of CrtM/BPH-651/PPi-Mg2+ complex (to be submitted to PDB) with FSPP.  Indeed, the 
ammonium ion is located in S1, and is very close (~1 Å) to position of farnesyl carbocation.  As 
a result, this ternary complex structure is more likely to mimick the proposed “transition state 1” 
in Figure 2.2B.  Also, we saw the PPi group forming ionic interaction with the quinuclidine 
ammonium, which explains why PPi enhances the compound’s activity. As mentioned in the 
previous section, the roles of Y129 and D52 in CrtM were not clear for their long distances to 
ligands.  This ternary complex suggested that D52 and Y129 are both involved in the interaction 
with PPi-Mg2+3 leaving group, and may facilitate of its departure.  As shown in Figure 2.12C, 
D52 directly chelates to a new Mg2+ (green sphere labeled D), and the same Mg2+ also interacts 
with the hydroxyl group of the Y129 sidechain, consistent with studies in SQS showed Y to F 
mutant was inactive.  
          Unlike other prenyl synthases, head-to-head synthases must host >2 carbocation sites since 
they catalyze the re-arrangement of the cyclopropane intermediates (following the 2nd ionizatioin, 
and ring-opening), in addition to ionizations.  Here, we demonstrated that carbocation-mimicking 
inhibitor, BPH-651, binds to both S1 and S2 sites, Figure 2.12D, corresponding to the 1st and 2nd 
transition states (Figure 2.2B), respectively.  It is possible that CrtM utilizes PPi-Mg2+ cluster to 
stabilize the S1 carbocation, but it is still unclear how the enzyme stabilizes the carbocation 
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species in S2 since no specific interactions were observed. Perhaps the ammonium groups (and 
the cationic reaction intermediates) were stabilized by the enzyme’s charge field, just as in FPPS 
(17).  
            The Eisai SQS inhibitors (E5700, ER119884, Scheme 2.1) do, however, both have an 
additional benzyl substituent that makes them particularly potent. So how might their bulky side-
chains bind?  To help answer that question, we first need to determine how good a model for 
SQS is CrtM (and vice-versa).  We therefore first obtained the x-ray crystallographic structure of 
BPH-652, the CrtM inhibitor whose structure we reported previously (10), bound this time to 
human SQS (PDB ID code 3LEE; full crystallographic details are given in Table 2.3). Using the 
CrtM/SQS protein structure alignment, Figure 2.11C, we find that there is a 2.0 Å rmsd between 
the BPH-652 ligand heavy atoms coordinates, showing close structural similarity. The rmsd 
reduces to 1.2 Å when the alignment is based solely on the conserved Asp residues, or 0.6 Å 
when the alignment is based solely on the ligands.  Second, we obtained the x-ray structure of an 
analog of BPH-652, BPH-702 (PDB ID code: 3ACY), which contains the benzyl substituent 
found in the most potent quinuclidinol inhibitors. As can be seen in Figure 2.11D, the 
phosphonosulfonate BPH-702 backbone binds in the S1 PPi-binding domain (seen in the FSPP 
structure); the biphenyl ether side-chain binds in the S2 side-chain region, while the benzene ring 
in the benzyl group is located at the terminus of the S1 side-chain in the FSPP structure.  When 
we superimpose the quinuclidinol (BPH-651) and benzyl biphenyl phosphonosulfonate (BPH-
702) structures, Figure 2.11E, we see that e.g. the ER119884 side-chain can readily fit into the 
space occupied by these two compounds, and a docking pose (using Glide)(26) for this potent 
inhibitor (docked to the CrtM/PSPP protein structure) illustrating this is shown in Figure 2.11F.  
Also of interest is the observation that the cationic center in the quinuclidinol overlays the PSPP 
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cyclopropane ring, Fig. 2.11F, suggesting that quinuclidinol may act as an isostere for a 
cyclopropyl carbinol carbocation reactive intermediate.  
Comparisons with Head-to-Tail Terpene Synthases, and Terpene Cyclases  These results 
lead to the following question: do the head-to-head, head-to tail and terpene cyclases all have the 
same basic “S1, S2” structure and function?  To help answer this question, we compared the 
CrtM/FSPP structure (PDB ID code 2ZCP) with the 3D structures of a series of other prenyl 
transferases: FPPS (27), GGPPS (16), epi-aristolochene synthase (28) and limonene synthase 
(29), where the donor/acceptor site functions are well known, to deduce, based on structural 
homology, which FPP in CrtM loses diphosphate (to form the cationic, prenyl-donor), and which 
acts as the nucleophile, or prenyl acceptor. We first aligned the head-to-tail prenyl synthase 
FPPS, containing zoledronate+isopentenyl diphosphate (IPP) (PDB ID code 2F8Z) to the 
CrtM/FSPP structure using the combinatorial extension (CE) program (30). The superposition 
(Figure 2.13A) indicates that the FSPP diphosphate in S1 (green in Figure 2.13A) is close to the 
bisphosphonate group in the allylic (cationic) site in FPPS, while the IPP diphosphate (and the 
IPP double bond) is in S2. The same conclusion is reached with FSPP in GGPPS, Figure 2.13B, 
the IPP molecule again being located in the S2 or prenyl acceptor site (yellow in Figure 2.13B). 
So, these results indicate that the S2 FPP acts as the nucleophile, in CrtM (and by analogy, in 
SQS and PHY). Similar results are found on comparison of the CrtM structure with those of the 
class I (ionization initiated) terpene cyclases epi-aristolochene synthase (Figure 2.13C) and 
limonene synthase (Figure 2.13D), with bound inhibitors. In both cases, the phosphonate or 
diphosphate headgroups bind in or close to the S1 diphosphate-Mg2+ cluster seen in CrtM, while 
the side-chains are in, or close to, the S2 site. Since it is clear that S1 in the cyclases has to be 
involved in ionization while the side-chain in S2 site acts as the nucleophile, we again deduce 
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that S1 site in CrtM is the cationic (prenyl donor) site, while S2 is the (olefinic) prenyl acceptor 
site. 
 
2.4 Conclusions 
Overall, the results provide the first detailed insights into the first committed reactions in sterol 
and carotenoid biosynthesis: the head-to-head condensation of two prenyl diphosphates to form a 
cyclopropylcarbinyl diphosphate, followed by ring opening to form DHS. We conclude that FPP 
in the bent S1 site ionizes to form the prenyl donor carbocation which then moves into the 
protein’s interior to react with the S2 site FPP C2,3 double bond, forming PSPP, completing the 
1st half reaction. In the 2nd half reaction, that the PSPP diphosphate then moves back to S1 to 
ionize.  Cationic inhibitors act as both farnesyl- and PSPP-carbocation isosteres, binding with 
their charge center in the regions of the allylic and the cyclopropyl carbocation group, 
respectively.  We also showed that S1+S2 binding mode (dual-site binding) is likely to be the 
origin of the potent activity of the quinuclidinols, and the phosphonosulfonate, BPH-702.  This 
information should be of interest in the context of developing novel types of CrtM/SQS 
inhibitors, as anti-infective drugs.  
 
2.5 Materials and Methods 
CrtM expression, purification, inhibition and site-directed mutagenesis  CrtM with a 
histidine tag was overexpressed in E. coli BL21(DE3) cells. A 50 mL overnight culture was 
transferred into 1L LB medium supplemented with 100 µg/mL ampicillin. Induction was carried 
out with 1mM IPTG for four hours, at 37 °C, when the cell culture reached an OD of 0.6 at 600 
nm. The cell extract was loaded onto a Ni-NTA column, and CrtM eluted by using a 100 mL 
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linear gradient of 0-0.5 M imidazole in 50 mM Tris-HCl buffer, pH 7.4. CrtM inhibition assays 
were carried out by using 96 well plates with 200 µL reaction mixture in each well. The 
condensation of farnesyl diphosphate was monitored by using a continuous spectrophotometric 
assay for phosphate releasing enzymes (32). The reaction buffer contained 25mM HEPES, 
0.5mM MgCl2, 250 µM FPP, pH 7.4. The compounds investigated (BPH-652, BPH-702) were 
pre-incubated with 2 μg CrtM for 30 minutes at 25 °C. The IC50 values were obtained by fitting 
the inhibition data to a normal dose-response curve in Origin 6.1 (OriginLab Corporation, 
Northampton, MA). Ki was calculated based on the IC50 value, and the reported kinetic constant 
of CrtM (33). IC50 values for BPH-651, BPH-673 in the presence of diphosphate were 
determined by using a radioactive assay, quantifying 3H-labled dehydrosqualene. In every 200 
µL reaction, 2 μg CrtM and inhibitor were pre-incubated in reaction buffer plus 25 µM PPi, for 
30 minutes, then 25 µM FPP and 25 nM 3H-FPP added. After 30 minutes, the reaction was 
quenched by EDTA and NaCl, 3H-dehydrosqualene was extracted using hexane, and quantified 
using a scintillation counter. CrtM mutants were prepared by using the QuikChange site-directed 
mutagenesis kit (Stratagene) in conjunction with the S. aureus CrtM gene template in the 
pET32Xa/LIC vector. The primers for performing site-directed mutagenesis were: 5’-
GTCATAAAATCATGAAGAAACATGCAAAAAGCTTTTCT-TACGC-3’ for S19A; 5'-
CAAAAAGCTTTTCTTACGCTGCTGACTTGTTACCAGAA-GATC-3' for F26A; 5’-
AAAGCGGTTTGGGCAATTTTTGCTGTGTGTCGTAAAAT-3’ for Y41F; 5’-
GCAATTTATGCTGTGTGTGCGAAAATTGATGAC-AGTAT-3’ for R45A; 5’-
GCTGTGTGTCGTAAAATTGCTGACAGTATAGATGTT-TATGGCG-3’ for D48A; 5’-
CGTAAAATTGATGACAGTATAGCTGTTTATGGCG-ATATTCAATT-3’ for D52A; 5'- 
CGGACGCTGAATTATTCGGAGCTTGTTATGGT-GTTGCTGG -3', for Y129A; 5’-
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AGGCTTGGTGAATCGTTGCTGTTGATTAATAT-ATTAAG-3’ for Q165L; 5’-
GCAATTGATTAATATATTAAGAGCTGTCGGTGAAG-ATTTTGAAA -3’ for D172A; 5’- 
ATTAAGAGATGTCGGTGAAGCTTTTGAAAAT-GAACGGAT-ATATT-3’ for D176A; 5’-
GAATTAGCAGCACGTATAGCTATTGAA-ATACTGGAC GAAG-3’ for 248A; 5’-
GCTAACTATACATTACATGAAGCGGTTTT-TGTGGAGAAGAGGAA-3’ for R265A. 
Mutations were confirmed by sequencing and were expressed in the same way as for the wild 
type protein. 
Truncated hSQS Expression and purification  The truncated hSQS (31-370) plasmid was the 
gift of Dr. Dolores González-Pacanowska of the Instituto de Parasitología y Biomedicina López-
Neyra, Spain. pET28a-hSQS was transformed into BL21 (DE3) CodonPlus RP cells (Novagen). 
Transformed cells were inoculated in Luria-Bertani broth (Lennox) with 30µg/mL kanamycin 
and 34 µg/mL chloramphenicol at 37°C and incubated at 200 rpm overnight. 5 mL of cells were 
then innoculated into 1L of LB broth with 30 µg/mL kanamycin and 34 µg/mL chloramphenicol 
at 37°C and 120 rpm and were induced using 0.1 mM of isopropyl β-D-1-thiogalactopynoside 
(IPTG) when the OD600 reached 0.6~0.8. Induced cells were incubated at 24°C overnight, then 
were harvested and frozen at -80°C. For purification, frozen cells were thawed and resuspended 
with loading buffer (500 mM NaCl, 10 mM CHAPS, 2 mM MgCl2, 10% glycerol, 10 mM β-
mercaptoethanol, 10 mM imidazole, Complete Protease Inhibitor Cocktail tablet (Roche), 
Benzonase nuclease and 20 mM phosphate buffer, pH 7.4). Resuspended cells were lysed by 
sonication, then centrifuged at 23,000 rpm for 30min. After centrifugation, supernatants were 
loaded onto a Ni-NTA column (GE Healthcare). The Ni-NTA column was equilibrated with 
wash buffer A  (500 mM NaCl, 10 mM CHAPS, 2 mM MgCl2, 10% glycerol, 10 mM β-
mercaptoethanol, 10 mM imidazole and 20 mM phosphate buffer, pH 7.4). Impurity proteins 
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were eluted by using 10% elution buffer A (500 mM NaCl, 10 mM CHAPS, 2 mM MgCl2, 10% 
glycerol, 10 mM β-mercaptoethanol, 500 mM imidazole and 20 mM phosphate buffer, pH 7.4), 
then the truncated (His)6-hSQS eluted by using 100% elution buffer. The (His)6-hSQS was then 
dialyzed against wash buffer B (150 mM NaCl, 10 mM β-mercapto-ethanol, 2 mM MgCl2, 20 
mM Tris, pH 7.4). After removal of the N-terminal poly-His tag by thrombin (Novagen), mature 
truncated protein was eluted using 100% elution buffer B (150 mM NaCl, 10 mM β-
mercaptoethanol, 2 mM MgCl2, 60mM imidazole, 20 mM Tris, pH 7.4). Fractions containing 
pure truncated hSQS were identified by SDS-PAGE, after which the protein was dialyzed against 
storage buffer (0.1 mM EDTA, 1 mM DTT and 20 mM Tris, pH 7.3) and stored at -80°C.  
X-Ray Crystallography Wild type and mutant CrtMs were eluted from Ni-NTA beads by 
incubation with Factor Xa (Novagen) to cleave it from the polyhistidine-containing N-terminal 
thioredoxin fusion tag. The cleaved product was equilibrated with buffer containing 150 mM 
NaCl, 5 mM DTT, 1 mM β-mercaptoethanol, 5 % glycerol and 20 mM Tris pH 7.5, then 
concentrated to 15 mg/mL. One set of PSPP/Y129A CrtM crystals were obtained by using 100 
mM potassium sodium tartrate, 30% PEG 3,350, 1 mM PSPP, and 2 mM MgCl2.. A second set 
of PSPP/Y129A as well as GGSPP/F26A CrtM crystals were obtained by co-crystallization in 
the presence of 0.5 mM PSPP or GGSPP, with 11-21% PEG4K, 0.3-0.4 M MgCl2 and 0.1 M 
Tris pH 8.5. Co-crystallization of CrtM-DHS was achieved by incubating 1mM PSPP+5mM 
MnCl2 in room temperature for ~3 hrs, then adding the crystallization solution (0.1M potassium 
sodium tartrate, 30% PEG 3,350). Native (WT) CrtM crystals (space group P3221) were grown 
by using the hanging-drop method by mixing equal amounts of reservoir with 0.12-0.58 M 
potassium sodium tartrate, at room temperature. Inhibitor bound crystals (BPH-651, BPH-673 
and BPH-702) were obtained by soaking with 0.05 mM ligand. All CrtM crystals (with the 
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exception of GGSPP/F26A CrtM), belonged to the P3221 space group and had similar lattice 
parameters.  The BPH-652 bound hSQS co-crystal was obtained by using the hanging-drop 
method by mixing equal amount of protein and reservoir (containing 20% PEG 6,000, 0.2 M 
sodium tartrate dibasic, pH 7.3, and 0.5 mM BPH-652). Crystals appeared after three days. The 
data were indexed, integrated and scaled by using the HKL2000 package (34) Structures were 
determined by using molecular replacement with the program Phaser (35). For CrtM, 2ZCP 
(minus ligands) was used as a starting model, while for hSQS, 1EZF (minus ligands) was used as 
template. Further model building and refinement employed Coot (36), Refmac (37, 38), CNS 
(39), and ProDRG server (40). Figures were obtained using PyMol (41). 
         FPP, FSPP, GGPP and GGSPP were synthesized according to literature methods(14, 31). 
PSPP was made biosynthetically by using hSQS. 50 mg of hSQS, 10 mg of FPP, together with 
20 units of baker’s yeast pyrophosphatase (Sigma-Aldrich) were dissolved in 10 mL reaction 
buffer (25mM HEPES, 100 mM NaCl, 0.5mM MgCl2, pH7.4). The reaction mixture was stirred 
at room temperature for 8 hours, then quenched by adding 10 mM EDTA, and solid NaCl. The 
solution was centrifuged at 4000g for 20 minutes, and the supernatant applied to a 5 mL C8 SPE 
column (SC300C8K, Western Analytical Products, Inc.). The column was washed with 10 mL 
reaction buffer and 10 mL 30% acetonitrile, sequentially, to remove residual enzyme, substrate, 
and other contaminants. PSPP was eluted using 40% acetonitrile (in water), and purity confirmed 
by LC-MS/MS. S- thiolo–PSPP was prepared using a similar procedure, except that FSPP and 
FPP (2:1) were used. LC/MS analyses were carried out using an Agilent LC/MSD Trap XCT 
Plus instrument. Compounds were separated on a 5 µm (4.6 x 150mm) Eclipse XDB-C8 column 
(Agilent) using a 0-100% acetonitrile (in 25mM NH4HCO3 buffer) gradient, and monitored by 
using negative-ion mode ESI. 
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2.6 Tables and Figures 
Table 2.1 Data collection and refinement statistics for CrtM with PSPP, GGSPP and DHS 
 
Crystals 
CrtM(Y129A)/PS
PP 
(3LGZ) 
CrtM(Y129A)/PS
PP 
(3ADZ ) 
CrtM(WT)/ 
PSPP 
(3NPR ) 
CrtM (F26A)/ 
GGSPP 
(3AE0) 
CrtM(WT)/ 
DHS 
(3NRI) 
Data collection 
Radiation source APS 23ID-D NSRRC BL13B1 APS 23ID-D PF BL5A APS 23ID-D 
Wavelength (Å) 1.0782 1.00000 1.0782 1.00000 1.0782 
Space group P32 2 1 P3221 P32 2 1 P3121 P32 2 1 
a(Å) 80.84 80.69 80.57 80.12 80.59 
b(Å) 80.84 80.69 80.57 80.12 80.59 
c (Å) 91.26 90.79 91.67 183.62 90.36 
Resolution (Å)a 30-2.40 30-1.89 30-2.00 30-2.37 30-2.85 
 (2.44-2.40) (1.96-1.89) (2.05-2.00) (2.45-2.37) (2.85-2.92) 
No. of reflections 13306 (685) 27821 (2720) 23228 (917) 28335 (2697) 8230 (224) 
Completeness (%) 96.3 (99.0) 99.9 (100) 97.06 (79.49) 99.1 (97.5) 98.9 (88.8) 
Redundancy 3.6 (3.7) 7.3 (7.5) 4.1 (2.3) 6.2 (5.7) 10.6 (5.8) 
Rmerge (%) 5.5 (34.2) 3.1 (32.3) 7.0 (45.5) 5.6 (58.1) 11.0 (44.4) 
I/s(I) 31.8 (4.3) 49.4 (5.2) 37.4 (2.0) 32.5 (3.1) 23.8 (2.4) 
Refinement 
No. of reflections 12637 (969) 26389 (3794) 21778 (1291) 26857 (3768) 7776 (395) 
Rwork (%) 20.3 (25.6) 16.8 (18.2) 19.76 (26.6) 21.9 (27.3) 20.7 (30.1) 
Rfree (%) 27.8 (43.5) 22.2 (24.8) 26.85 (35.8) 28.1 (33.4) 30.7 (48.9) 
Geometry deviations 
Bond lengths (Å) 0.018 0.007 0.006 0.007 0.004 
Bond angles (°) 1.66 1.4 1.2 1.5 0.5 
Mean B-values ( Å2) / No. 
Protein atoms 42.33/2342 23.2 / 2385 39.21 / 2392 30.7 / 4772 48.9 / 2353 
Compound atoms 54.45/39 28.2 / 39 31.9 / 39 67.7 / 116 64.0 / 30 
Mg ions 56.51/2 32.8 / 2 42.5 / 2 56.3 / 6 - 
Water molecules 46.28/68 33.3 / 263 45.0 / 203 30.8 / 70 - 
Ramachandran plot (%) 
Most favored 95.5 95.2 96.8 93.0 94.9 
Additionally allowed 4.5 4.8 2.8 7.0 4.0 
Generously allowed 0 0 0.4 0 1.1 
aValues in the parentheses are for the highest resolution shells.  
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Table 2.2 Reactivity of four isoprenoid diphosphates (FPP, FSPP, GGPP, GGSPP) bound to S1 
or S2 in CrtM showing products formeda 
 
  FPP(S1) FSPP(S1) GGPP(S1) GGSPP(S1) 
FPP(S2) PSPP       
FSPP(S2) S-PSPP N.R.     
GGPP(S2) C35-PSPP N.R. 
N.R. [WT]; 
F26A shows 
activity in 
coupling assay 
  
GGSPP(S2) C35-S-PSPP N.R. N.D. N.D. 
        aN.R. = no reaction; N.D. = not determined 
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Table 2.3 Data collection and refinement statistics for CrtM and hSQS with inhibitors 
Crystals 
CrtM (WT)/ BPH-
651 
(3ACW) 
CrtM/BPH-673 
(3ACX) 
hSQS/BPH-652 
(3LEE) 
CrtM/ 
BPH-702 
(3ACY) 
Data collection 
Radiation source NSRRC BL13B1 
NSRRC 
BL13B1 
NSLS X29A NSRRC BL13B1 
Wavelength (Å) 1.0000 0.9732 1.0809 0.9732 
Space group P32 2 1 P32 2 1 P21 P32 2 1 
a(Å) 80.66 80.63 85.66 80.50 
b(Å) 80.66 80.63 153.42 80.50 
c (Å) 90.22 90.45 92.90 90.79 
Resolution (Å)a 30-1.63 30-1.31 30-3.20 30-1.84 
 (1.69-1.63) (1.36-1.31) (3.31-3.20) (1.91-1.84) 
No. of reflections 42617 (4208) 81916 (8101) 39260 (3898) 29936 (2955) 
Completeness (%) 99.5 (100) 99.9 (100) 100 (99.7) 99.7 (100) 
Redundancy 3.4 (3.4) 9.5 (9.3) 7.3 (6.7) 4.6 (4.6) 
Rmerge (%) 3.2 (48.7) 3.0 (22.2) 12 (44.9) 6.4 (48.6) 
I/s(I) 35.4 (2.1) 66.3 (9.7) 16.6 (3.9) 29.1 (4.2) 
Refinement 
No. of reflections 40455 (5829) 77731 (11213) 37261 (2672) 28389 (4064) 
Rwork (%) 17.4 (21.9) 16.0 (15.5) 20.6 (26.6) 16.7 (19.4) 
Rfree (%) 20.3 (28.2) 18.2 (19.5) 27.2 (37.0) 21.8 (28.8) 
Geometry deviations 
Bond lengths (Å) 0.007 0.007 0.006 0.007 
Bond angles (°) 1.5 1.5 0.742 1.5 
Mean B-values ( Å2) / No. 
Protein atoms 22.5 / 2392 10.6/2392 68.89/15526 18.8/2392 
Compound atoms 40.8/21 12.4/23 55.04/150 39.7/32 
Mg ions - - 35.97/6 34.8/1 
Water molecules 34.6/287 23.3/453 65.37/189 29.3/307 
Ramachandran plot (%) 
Most favored 95.9 95.6 91.1 95.6 
Additionally allowed 3.7 4.1 8.6 4.4 
Generously allowed 0.4 0.4 0.3 0 
                aValues in the parentheses are for the highest resolution shells. 
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Figure 2.1 (A) Schematic illustration of the reactions catalyzed by “head-to-head” terpene 
synthases: dehydrosqualene synthase (CrtM), squalene synthase (SQS) and phytoene synthase 
(PSY).  All reactions involve an initial C1′-2,3 cyclopropanation step.  The end products of the 
biosynthetic pathways are highly varied and include sterols (cholesterol, ergosterol) and 
carotenoids (staphyloxanthin, β-carotene). (B) Proposed catalytic mechanism and transition 
states of CrtM. G=geranyl group. 
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Figure 2.2 Crystallographic results for CrtM with a bound substrate-like inhibitor FSPP and the 
intermediate PSPP.  (A) Bound FSPP (PDB code ID 2ZCP), from Ref. 10.  (B) 2Fo-Fc map for 
PSPP contoured at 1σ (green) and 3σ (red) (PDB code ID 3ADZ).  (C) Superposition of PSPP 
(PDB ID code 3ADZ) on FSPP in CrtM. 
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Figure 2.3 Effects of site-directed mutagenesis on CrtM catalytic activity.  The results in the 
table at the top shown CrtM residues rank-ordered by SCORECONS (42) conservation score 
together with the effects that mutations to Ala have on 1st as well as 2nd half activity. Traces at 
bottom are GC/MS traces showing how mutations affect dehydrosqualene formation.  The two 
DHS isomer peaks shown below are the extracted ion chromatogram of m/z = 408 (C30H48+.). 
The quantification of DHS is done by peak integration, using squalene (10 ug/mL, m/z = 410, 
C30H50+.) as an internal standard. 
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Figure 2.4 Ligand electron densities of CrtM (Y129A)/PSPP (3LGZ), CrtM (WT)/PSPP 
(3NPR), and superposition of the three CrtM/PSPP structures. (A) 2Fo-Fc map of CrtM (Y129A) 
/PSPP [PDB ID code 3LGZ]. (B) 2Fo-Fc map of CrtM (WT)/PSPP [PDB ID code 3NPR]. (C, 
D) Superpositions: PDB ID code 3ADZ in green, 3LGZ in grey, 3NPR in cyan. The main 
difference between 3LGZ and 3ADZ is in the location of the second Mg2+ and likely arises due 
to the large difference in [Mg2+] in the crystallization buffers (2 mM, 0.3-0.4 M), while 3NPR 
and 3ADZ are virtually identical. 
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Figure 2.5 Effects of FSPP on CrtM catalysis, and a GGSPP inhibitor structure.  (A) Rate of PPi 
generation increases with FSPP concentration (error bars are from duplicate data points, 
R2=0.85).  (B) Rate of dehydrosqualene formation decreases with FSPP concentration (duplicate, 
R2=0.78). These results indicate “dead-end” formation of S-thiolo-PSPP, as confirmed by mass 
spectrometry. (C) 2Fo-Fc map (contoured at 0.8σ and 3σ) of GGSPP bound to F26A CrtM. (D) 
GGSPP (green and yellow) binds to both S1, S2; would clash with F26 (in red) if present; FSPPs 
are in cyan. 
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Figure 2.6 High-resolution mass spectrometry results for FSPP/FPP/CrtM reaction product (after 
purification and NaBH4 reduction) and MS/MS spectra of S-thiolo-PSPP. 
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Figure 2.7 LC/MS results for the FPP+GGSPP CrtM catalyzed reaction. The top four panels 
show the extracted ion chromatograms (EIC) for FPP, GGSPP, PSPP, and C35-thiolo-PSPP. The 
mass spectrum of the C35-thiolo-PSPP product (at 24.4 minutes) is shown in the bottom panel. 
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Figure 2.8 LC/MS results for FSPP+GGPP CrtM catalyzed reaction. Top two panels show the 
extracted ion chromatograms (EIC) of the substrates (FSPP, GGPP). PSPP and C35-thiolo-PSPP 
products were not detectable (3rd and 4th panels). 
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Figure 2.9 Schematic illustration of the conversion of FPP to dehydrosqualene catalyzed by 
CrtM, based on the crystallographic results. (A) Bound FPP in S1 ionizes.  (B) Carbo-cation 
reacts with S2 FPP alkene group. (C) PSPP PPi in S2 moves to S1 site. (D) PSPP PPi ionizes. 
(E,F) Carbocation rearranges and after proton loss forms final product, dehydrosqualene. (G), 
(H) Two possible condensation reactions, in S1, S2. Only that shown in G  is consistent with the 
crystallographic results. 
 
 
Figure 2.10 Dehydrosqualene structure; important residues in catalysis, and PSPP ionization 
model. (A) 2Fo-Fc map for dehydroqualene (1σ, magenta) bound to CrtM surface pocket, 
superimposed on PSPP (in cyan). (B) Key catalytic residues: D48, D52 and R45 are essential for 
2nd half reaction and indicate PPi ionization in S1. (C) Proposed movement of PSPP PPi into S1 
for ionization; PSPP is in gray, and the proposed ionization conformation of PSPP in cyan. The 
ionization conformation is obtained by using Glide program (26), docking to PDB ID code 2ZCP.    
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Figure 2.11 X-ray crystallographic structures of inhibitors bound to CrtM. (A) BPH-651, a 3-OH 
quinuclidine (PDB ID code 3ACW).  (B) BPH-673 (PDB ID code 3ACX), an 
biphenyl/ammonium inhibitor.  Both structures are shown superimposed on PSPP (PDB ID code 
3ADZ, in cyan).  (C) Comparison between BPH-652 bound to CrtM (orange; PDB ID code 
2ZCQ) and SQS (green; PDB ID code 3LEE).  The heavy atom rmsd in 2.1 Å but this reduces to 
1.2 Å if the structures are aligned using the conserved Asp residues (or 0.6Å for the ligands 
alone).  The apparent “offset” may be related to an NADPH binding site in SQS.  (D) BPH-702 
(orange) bound to CrtM superimposed on the FSPP structure (in green, yellow).  Note that the 
phosphonosulfonate group binds in S1, the biphenyl ether side-chain in S2, while the benzyl 
substituent also binds in S1. (E) BPH-702 (the benzyl inhibitor, in orange) superimposed on the 
quinuclidine BPH-651.  (F) Docking pose for the quinuclidine ER119884 (in yellow) bound to 
CrtM, superimposed on PSPP (in cyan). 
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Figure 2.12 Crystal structure of a CrtM/BPH-651/PPi-[Mg2+]3 ternary complex, and the 
comparison of 2 different cationic sites.  (A) 2Fo-Fc density map contoured to 1.5σ (grey), and 
in 3.0σ (magenta) (B) Superposition of BPH-651 in the ternary complex with S1 FSPP.  BPH-
651 is colored in yellow, S1 FPP shown as thinner green stick. The ammonium ion of BPH-651 
aligned very closely with the S1 carbocation.  (C) BPH-651 ternary complex structure indicated 
the interactions of Y129 and D52 with PPi/Mg2+ cluster; PPi was shown in thick stick model, 
and diphosphate group of FPP substrate in thin sticks. Mg2+ ions from ternary complex in blue,  
Mg2+ ions from substrate structure in green. (D) Overlay of two BPH-651 structures indicated 
two separate carbocation binding positions in S1 and S2.  
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Figure 2.13  Stereo views of the alignments of dehydrosqualene synthase (CrtM) with various 
terpene synthases and cyclases, highlighting the location of the S1 (cationic, prenyl donor) and 
S2 (olefinic, prenyl acceptor) sites.  (A) CrtM aligned to farnesyl diphosphate synthase (1D code 
PDB 2F8Z) containing a bisphosphonate inhibitor (zoledronate) and isopentenyl diphosphate 
(IPP).  (B) alignment of CrtM with human geranylgeranyl diphosphate synthase (PDB ID code 
2Q80) containing geranylgeranyl diphosphate (GGPP) and IPP.  (C) alignment of CrtM (PDB ID 
code 2ZCP) with epi-aristolochene synthase (PDB ID code 5EAU) from Nicotiana tabacum 
containing a substrate analog (trifluorofarnesyl diphosphate).  (D) alignment of CrtM with 
limonene synthase (PDB ID code 2ONG) from Mentha spicata containing dimethylhexyl 
trihydrogen diphosphate. 
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Chapter 3 
Phosphonosulfonates Are Potent, Selective Inhibitors 
of Dehydrosqualene Synthase and Staphyloxanthin 
Biosynthesis in Staphylococcus aureus 
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3.2   Introduction 
Staphylococcus aureus is a major human pathogen, producing a wide spectrum of 
clinically significant hospital- and community-acquired infections. Methicillin-resistant strains of 
S. aureus (MRSA) have now reached epidemic proportions, and pose a significant challenge to 
the public health. A recent CDC study has shown that more people in the United States die from 
invasive MRSA each year than do from HIV/AIDS (1,2). There is, therefore, an urgent need to 
find new therapies. One unconventional approach to anti-infective therapy involves blocking 
bacterial virulence factors (3), a potential benefit of this strategy being that, without the “life or 
death” selective pressure exerted by classical antibiotics, bacteria may be less prone to develop 
drug resistance. 
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An important virulence factor of S. aureus is the golden carotenoid pigment, staphyloxanthin 
(STX), whose numerous double bonds can react with, and thus deactivate, the reactive oxygen 
species (ROS) generated by neutrophils and macrophages, making S. aureus resistant to innate 
immune clearance (4,5). STX has been shown to be essential for infectivity: bacteria that lack 
staphyloxanthin are nonpigmented, are susceptible to neutrophil killing, and fail to produce 
disease in a mouse skin and systemic infection models (4,6). STX biosynthesis is thus a novel 
target for preventing or treating S. aureus infections. The first committed step in STX 
biosynthesis is catalyzed by the enzyme dehydrosqualene synthase, also called diapophytoene 
synthase or CrtM, and involves the head-to-head condensation of two molecules of farnesyl 
diphosphate (FPP) to produce the C30 species, presqualene diphosphate, which is then converted 
to dehydrosqualene (Figure 3.1A) (5). Since this condensation is remarkably similar to the first 
step in mammalian cholesterol biosynthesis (Figure 3.1B), we reasoned that known squalene 
synthase inhibitors, developed in the context of cholesterol-lowering therapy, might also inhibit 
dehydrosqualene synthase. This turns out to be the case and we recently reported that 
phosphonosulfonates such as 1 (BPH-652 or rac-BMS-187745), developed by Bristol-Myers 
Squibb and advanced through phase I/II human clinical trials (7,8), potently inhibit S. aureus 
CrtM, as well as STX biosynthesis in the bacterium6. Upon treatment with 1, the resulting non-
pigmented S. aureus are much more susceptible to killing by hydrogen peroxide, and are less 
able to survive in freshly isolated human whole blood than are normally pigmented S. aureus. 
Moreover, in an in vivo systemic S. aureus infection model, the bacterial counts in kidneys of 
mice treated with 1 were reduced by 98%, compared to those of a control group. These results 
show that 1 represents a novel lead compound for virulence factor-based therapy of S. aureus 
infection. Here, we report the synthesis and testing of a library of 38 phosphono-sulfonates and 
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related bisphosphonates against CrtM, against STX biosynthesis in S. aureus and, as a 
counterscreen, against an expressed human squalene synthase. We report both qualitative as well 
as quantitative (QSAR, quantitative structure activity relationships) results for CrtM and STX 
biosynthesis inhibition, as well as CrtM/SQS selectivity. In addition, we investigate how cell 
activity can be predicted from enzyme (CrtM) inhibition results, opening the way to the further 
development of potent and selective inhibitors of S. aureus virulence. 
 
3.3 Results and Discussion 
Qualitative Structure-Activity Relationships in CrtM Inhibition 
The inhibitor class we investigate here originated in early research aimed at developing human 
squalene synthase inhibitors as cholesterol lowering drugs. Early SQS inhibitors were based on 
the structure of FPP, the substrate for SQS, with the labile diphosphate group being replaced by a 
bisphosphonate. However, isoprenyl sidechains were metabolized in vivo. This could be 
overcome by incorporation of e.g. a biphenyl isostere (e.g., 2) (9): 
 
but these compounds potently bound to bone, in addition to causing elevation in liver enzymes. 
Phosphonosulfonates, on the other hand, bound only weakly to bone, and the diphenyl ether 
phosphonosulfonates (such as 1) were not broken down and did not cause elevated liver function 
(10). Plus, in our previous work we found that 1 had promising activity against CrtM as well as 
cellular and in vivo activity6. In the present study, we sought to develop more potent CrtM 
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inhibitors with improved activity in S. aureus cells that, at the same time, have poor activity 
against human SQS, reducing formation of the 1,10-dioic acid FPP metabolite that is formed as a 
result of SQS inhibition. We first synthesized a small library of five diphenyl ether 
phosphonosulfonates, five biphenyl phosphonosulfonates and three biphenyl bisphosphonates, 
based in part on the types of compound tested previously as SQS inhibitors, and examined them 
for their activity against CrtM. The structures and IC50 values (in parentheses) in CrtM inhibition 
of these compounds are shown in Figure 3.2. Bisphosphonates (2 and 3) are the most potent 
CrtM inhibitors (IC50 = 0.5 and 0.2 µM, or Ki = ~ 1 and 0.5 nM), being an order of magnitude 
more active than are any of the phosphonosulfonates. However, these compounds were found to 
have only modest activity in inhibition of STX biosynthesis in S. aureus (see below), due 
perhaps to poor cell uptake. Compound 4 (IC50 = 5.4 µM), an analogous phosphinophosphonate 
compound, was ~10x less active than was 2, showing similar activity in CrtM inhibition as the 
phosphonosulfonates, which are likely to have the same formal charge. For the 
phosphonosulfonates with diphenylether sidechains, 5 and 6 (which contain parasubstituted 
fluoro and n-propyl groups, respectively) were ~4x as active (IC50 = 2.3 and 2.2 µM, or Ki = ~ 5 
nM) as 1. Compound 7 (IC50 = 7.2 µM), containing a paratrifluoromethyl substituent, showed 
similar activity to that found with 1, while 8, which contains an ortho-benzyl group, was ~ 5x 
less active than 1 (IC50 = 37.2 µM). The phosphonosulfonates containing biphenyl sidechains (9 
– 13) had, in general, significantly reduced activities. 
These results, together with the bacterial cell-based results discussed below, are of 
interest since they show that the biphenyl bisphosphonates are the most potent CrtM inhibitors, 
with IC50 values of <1 µM. They do, however, have poor cell-based activities, with IC50 > 1 µM 
and consequently, were not selected for further development. The biphenyl phosphonosulfonates, 
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on the other hand, had generally poor activity against CrtM (average IC50 for the five compounds 
investigated ~50 µM), making them also less attractive candidates for development. However, 
the diphenyl ether phosphonosulfonates had, on average, an IC50 value of ~11 µM (or a Ki of ~ 
30 nM), plus, these compounds were very potent in cell based assays (i.e. in inhibiting STX 
biosynthesis by S. aureus), as discussed in detail below, and were thus selected for further 
development. 
To see if major improvements in CrtM activity might be obtained by modifying the 
phosphonosulfonate sidechain, we next synthesized the eight analogs of 1, shown in Figure 3.3, 
in which we modified the sidechain heteroatom (O → NH, CH2 and a carbazole); the position of 
the heteroatom (meta → para); the length of the alkyl sidechain (N = 1, 2 and 3 CH2 groups), 
plus, we synthesized the R and S-enantomers of 1, since previously the S-form was found to for 
more potent than the R-form, in inhibiting SQS (11). The optically active (S)-1 (IC50 = 1.4 µM) 
was ~ 30x more active than its (R)-enantiomer in CrtM inhibition (Figure 3.3). Shorter linkers 
between the aromatic ring and phosphonosulfonate headgroup, as found in 14 and 15, led to 
essentially no CrtM activity (IC50 > 500 µM). As for compounds 16 (IC50 = 43.7 µM) and 17 
(IC50 = 20.4 µM), replacing the bridging -O- atoms with -NH- and -CH2-, respectively, resulted 
in reduced CrtM inhibition activity. The 4-phenoxyphenyl analog (18) was slightly more active 
than its 3-phenoxyphenyl counterpart (1) in CrtM inhibition but was less active in the cell based 
assay, while compound 19, a fused tricyclic analog, had very poor activity against CrtM (IC50 = 
170 µM). These results, together with those discussed above, clearly indicated that investigating 
additional diphenyl ether phosphonosulfonates would be of interest. 
We therefore next synthesized 17 more substituted phosphonosulfonates whose structures 
and activities in CrtM inhibition are shown in Table 3.1, together with the previously described 
 55 
results for 1, 5 - 7. The following structure-activity relationship features can be seen from these 
results: (1) Diphenyl ether phosphonosulfonates substituted with F-or-CF3 had diminished 
activity when the substituent was in the 2′-position relative to the corresponding 3′- or 4′-
substituted analogs.  (2) Halogen-containing groups, including F, CF3 and Cl, generally enhance 
activity. (3) Alkyl groups with various shapes and sizes located at the 4′-position result in 
modest activity changes (when compared to 1), while oxygen-containing groups at the same 
position significantly decrease activity. (4) Di-halogen substituted compounds are more active 
than the parent compound, 1. (5) Substitution at the 6-position with F has little effect on activity 
but incorporation of an OMe group in this location abrogates most activity.  Clearly, the above 
represents a complex set of empirical observations that require a more quantitative analysis. 
Quantitative Structure-Activity Relationships in CrtM Inhibition  To investigate the 
structure-activity relationships outlined above, we carried out a comparative molecular similarity 
indices analysis (CoMSIA) (12) of the CrtM inhibition activities of these phosphonosulfonate 
compounds. All molecules were constructed and minimized using the MMFF94x forcefield in 
the program MOE (13). Compounds were then aligned using the flexible alignment module (14) 
in MOE, which perceives common features within the molecules (e.g., similar partial charge, H-
bond acceptor, aromaticity, hydrophobicity, etc.). We used fully deprotonated 
phosphonosulfonate head groups, based on the observation that 1 binds two Mg2+ in the CrtM 
active site6, and our previous NMR and quantum chemical studies on bisphosphonates, which 
indicate deprotonation when bisphosphonates bind to Mg2+ (15). All compounds were 
constructed with the (S)-configuration, based on the observation that (S)-1 is far more active than 
is its (R)-enantiomer in CrtM inhibition (as also found in SQS inhibition 10). The aligned 
compounds were exported into Sybyl (16), then we used a partial least-squares (PLS) method to 
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regress the CrtM inhibitory activity and CoMSIA field data. The 3-D QSAR model yielded r2 = 
0.98, q2 (no. of components) = 0.72 (7), F-test = 245.8, and a pIC50 error of 0.12, as shown in 
Table 3.2. To further validate the model, we performed five leave-five-out training/test sets, 
obtaining on average a factor of 1.8x error between predicted and experimental IC50 values 
(Table 3.2). The compound alignment and the CoMSIA fields are shown in Figure 3.4. There is a 
relatively large hydrophobic contribution (46.6%) to the CoMSIA model, followed by steric 
(25.2%), electrostatic (19.9%) and H-bond donor (8.3%) interactions. The CoMSIA results are in 
good agreement with the more qualitative experimental observations: steric and hydrophobic-
favorable areas (in green and magenta, respectively, in Fig. 4B, C) at the 3′- and 4′-positions 
correspond to generally increased activities of 1 analogs with para- and meta-substituents on the 
distal phenyl ring. Two large steric penalty areas (in red in Fig. 4B) at the 4- and 6- positions of 
the proximal phenyl ring account for the decreased activity of the biphenyl phosphonosulfonates 
(9 - 13 in Fig. 2) and 36 (entry 21 in Table 3.1). In addition, a positive-charge-favored region (in 
blue, shown in Fig. 4D) within the distal phenyl ring help account for the enhanced activity of 
the (electron-withdrawing) halogen containing phosphonosulfonates (e.g., 5, 24 and 30). The 
negative-charge favored area (in yellow, Fig. 4D) obviously correlates with the activity of the 
bisphosphonates (2 and 3) in CrtM inhibition, since the sulfonate group is replaced by the more 
negatively-charged phosphonate group. 
Staphyloxanthin Biosynthesis Inhibition  The results described above are of interest since they 
indicate that dehydrosqualene (CrtM) can be potently inhibited by phosphonosulfonates, and by 
bisphosphonates. The question next arises: how potent are these compounds in inhibiting STX 
biosynthesis in S. aureus? We thus treated S. aureus bacteria with serially diluted compounds at 
37°C for 3 days, after which the STX pigment was extracted with methanol. Optical densities 
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were measured at 450 nm and IC50 values for inhibition of pigment formation for each compound 
were calculated using a standard dose-response curve. The rank ordered IC50 values of the 38 
compounds investigated are shown in Table 3.3.  Surprisingly, we found that STX biosynthesis 
inhibition in S. aureus was poorly correlated with CrtM (enzyme) inhibition, with an R2 = 0.27 
for the CrtM/STX inhibition pIC50 values, as shown in Figure 3.5A. 
Presumably, this poor correlation is due to the fact that no consideration of cell 
permeability or drug uptake is involved in the in vitro enzyme inhibition data. To try to take this 
into account, we therefore chose to use SlogP (the logarithm of the octanol/water partition 
coefficient (17) to describe this effect by using the following equation: pIC50 (STX, cell) = 
a•pIC50 (CrtM) + b•SlogP + c (1) 
where a, b and c are regression coefficients from a linear regression analysis. This yielded 
an R2 = 0.60 for the experimental-versus-predicted pIC50 values (Figure 3.5B) or an R2=0.53 for 
a leave-two-out (L2O) prediction test set, to be compared with R2 = 0.16 for a L2O test set of 
predictions using solely the enzyme pIC50 results. Of course, there is no a priori reason to use 
SlogP as the extra descriptor, or to limit the method to use of a single extra descriptor. So we 
next used a three descriptor model: 
pIC50 (STX, cell) = a•pIC50 (CrtM) + b•B + c•C + d 
where B, C are all possible descriptor pairs available in MOE that have non-Boolean 
values (i.e. the properties do not contain 0’s or 1’s). The top 10 “enzyme plus two descriptor” 
results contains pIC50 (CrtM) as the major descriptor, and the R2 value obtained for the top 
solution, R2 = 0.72, is clearly an improvement over that obtained using solely CrtM or CrtM and 
SlogP results (Figure 3.5C). We then used a leave two out method to produce a test set result in 
which we recomputed all training sets minus the two compounds of interest, then used the 
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coefficients and descriptors to predict the two omitted compounds. In this way, the activity of 
each compound was predicted 37 times. The R2 in this leave two out test set was R2 = 0.62, a 
major improvement over the R2 = 0.16 using solely enzyme inhibition data (and the same leave 
two out test set approach). To verify that this predictivity did not occur by chance, we repeated 
the leave two out process, using scrambled cell activity data. This process was repeated 10 times, 
with the average R2 values (leave two out, scrambled) being R2 = 0.10. Clearly, then, 
phosphonosulfonates are potent inhibitors of the CrtM enzyme, and their activity can be 
relatively well predicted by using the combinatorial descriptor search method, even when the 
cell/enzyme data is very poorly correlated.  Moreover, as might be expected based on the 
enzyme inhibition results (Figure 3.3), (S)-1 is far more active than is (R)-1, in cells (Table 3.3). 
Selectivity of CrtM Inhibition  Since phosphonosulfonates, such as 1, were originally 
developed as inhibitors of squalene synthase in the context of cholesterol-lowering therapy 
(7,8,10), we were also interested to see how they inhibit human SQS, since SQS inhibition 
results in formation of a 1,10-dioic acid metabolite (from unused FPP). We thus screened each of 
the compounds described above for their activity against an expressed human SQS enzyme. 
Results are shown in Table 3.4. We find that CrtM inhibition is moderately correlated with 
human SQS inhibition, R2 = 0.50, as shown in Figure 3.5D, consistent with the modest sequence 
homology of S. aureus CrtM and human SQS (30% identity, 36% similarity)6. Of course, this 
modest correlation reflects something that is potentially beneficial: that some good CrtM 
inhibitors are poor hSQS inhibitors. Consider for example the 4′-n-propyl species 6 (Table 3.1). 
This compound has a 2.2 μM IC50 versus CrtM and a 1.9 μM IC50 versus hSQS, Table 3.4, and 
is therefore a much poorer hSQS inhibitor than is the parent compound, 1. For compound 1 (used 
previously in vivo6), the CrtM IC50 is 7.9 µM but 1 is a very potent hSQS inhibitor with an IC50 
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of 23 nM, Table 3.4. The results shown in Table 3.4 are rank ordered in terms of selectivity for 
CrtM over hSQS inhibition or IC50(hSQS)/IC50(CrtM), such that a larger number means more 
CrtM selectivity, and are also given in terms of selectivity relative to 1, that is 
selectivity(compound)/selectivity(1). The compound with the highest relative selectivity is thus 6, 
which is (1.9/2.2)÷(0.023/7.9) or ~300x more selective a CrtM inhibitor than is 1. Remarkably, 
both 1 and 6 have, however, very similar IC50 values for STX biosynthesis (Table 3.3): 110 nM 
for 1 and 93 nM for 6. These results strongly suggest that it is possible to make potent inhibitors 
of STX biosynthesis (such as 6) that have much better relative selectivity in inhibiting SQS than 
does 1. 
To put these observations on a more structural basis, we carried out a QSAR/CoMSIA 
analysis, using the relative selectivity results. Using the same compound alignment as shown in 
Fig. 4A, we obtained r2 = 0.94, q2 = 0.54 (6), F-test = 76.5, and a pIC50 error of 0.20, as shown in 
Table 3.4.  We also validated this model by using five leave-three-out training/test sets, finding 
on average a factor of 1.8x error between predicted and experimental IC50 values (Table 3.4). 
There is a large hydrophobic contribution (54.8%) to the CoMSIA field results, followed by 
steric (29.5%) and electrostatic (15.7%) fields. The CoMSIA fields are shown in Figure 3.6 and 
it is clear that overlapping steric (green, Fig. 6A) and hydrophobic (magenta, Fig. 6B) field 
features near the 4′-position are favored for CrtM selectivity. Hydrophobic (white, Fig. 6B) and 
a steric (red, Fig. 6A) disfavored regions are located near the 2′ - and 3′ -positions, 
respectively, and are responsible for the poor selectivity of compounds such as 8 and 21. 
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3.4    Conclusions 
         The results described above are of interest for a number of reasons. First, we made 38 
phosphonosulfonate and bisphosphonate compounds and investigated their activity in inhibiting 
S. aureus dehydrosqualene synthase (CrtM), the enzyme involved in the first committed step in 
the biosynthesis of the virulence factor, staphyloxanthin, in S. aureus. The most active 
compounds were bisphosphonates, but they had poor activity in cells, while many 
phosphonosulfonates were active in both enzyme and cell assays.  Second, we developed a 
QSAR model for CrtM inhibition that had good predicitivity. Third, we determined the activity 
of each compound against staphyloxanthin biosynthesis, in S. aureus. The pIC50 results were 
poorly correlated (R2 = 0.27, training; R2 = 0.16, test set) with the enzyme inhibition pIC50 
values. However, using a combinatorial descriptor search, we obtained significant improvements 
in cell activity predictions with R2 = 0.72 (training) and R2 = 0.62 (test set) results. Fourth, we 
investigated the inhibition of human squalene synthase by these compounds, and used a QSAR 
method to enable good predictions of CrtM/SQS selectivity, relative to that exhibited by 1.  
Several CrtM inhibitors (e.g., 6 and 25) also showed very potent activity in bacterial cell-based 
assays. Overall, these results are of general interest since they demonstrate that diphenylether 
phosphonosulfonates are potent inhibitors of dehydrosqualene synthase and of the STX 
biosynthesis in S. aureus and as such, they have considerable potential for further development in 
a new approach to combating S. aureus infections. 
 
3.5   Materials and Methods 
Computational methods  CoMSIA analysis was performed with default settings in Sybyl16 
(version 7.3). All compounds were geometrically optimized, using the MMFF94x forcefield, 
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then aligned in the program MOE13, utilizing the flexible alignment module (14).  The 
alignment was carried out by performing up to 1,000 flexible refinement iterations using a 
gradient test of 0.01 to 1.0 with hydrophobe, logP, and partial charge similarity features, as well 
as the default options (H-bond donor, acceptor, aromaticity, polar hydrogens and volume). The 
alignments were exported into the Sybyl program, where atomic charges were determined by 
using the Gasteiger-Marsili method (22). CoMSIA indices were calculated on a rectangular grid 
containing each of the sets of aligned molecules using steric, electrostatic, hydrophobic, H-donor 
and acceptor fields, using default grid spacing and probe atoms. We then used a partial least-
squares (PLS) method to correlate the 3D structural features with activity. The optimal number 
of components was determined with the SAMPLS cross validation method (23). Each of the 
QSAR models was then validated by performing five training/test sets. 
For cell activity predictions, a set of 117 molecular descriptors, including SlogP (17), were 
computed within MOE and exported to MATLAB (24) for a combinatorial descriptor search. 
The entire descriptor space was searched exhaustively to find the combinations of descriptors, 
which gave the best regression coefficient (highest R2) for the equation: 
pIC50 (pigment) = a•pIC50 (Enzyme) + b• B + c•C + d 
where B and C are MOE descriptors and a – d are coefficients. A leave-two-out cross-validation 
was performed to test the predictivity of the model, where all combinations of 2 compounds were 
excluded from the data set and the descriptor combinations reevaluated for the remaining 
(training set) compounds. The regression equation obtained from each run was then used to 
calculate the cell activity of the left out compounds (the test set) and the R2 from all such leave-
two-out predictions is reported in the text.  Finally, a scrambling analysis was performed in 
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which the cell activity values for all the compounds were scrambled, and the leave-two-out 
cross-validation performed using the scrambled data set. 
CrtM enzyme inhibition assay  The expression and purification of the S. aureus CrtM as well 
as the inhibition assays were carried out by using our previous methods6. In brief, CrtM with a 
histidine tag was overexpressed in E. coli BL21 (DE3) cells. After an overnight growth, an initial 
50 mL culture was transferred into 1 L LB medium supplemented with 100 µg/mL ampicillin. 
Induction was carried out with 1mM IPTG for four hours, when the cell culture reached an OD 
of 0.6 at 600 nm. Protein was purified with a Ni-NTA column, using a 100 mL linear gradient of 
0-0.5 M imidazole in 50 mM Tris-HCl buffer at pH 7.4. Enzyme inhibition assays were carried 
out, in duplicate, in 96 well plates, with a total of 200 µL reaction mixture in each well. The 
reaction was monitored by using a continuous spectrophotometric assay for phosphate releasing 
enzymes25. The reaction buffer contained 50 mM Tris-HCl, 1mM MgCl2, 450 µM FPP, pH 7.4. 
The compounds investigated were pre-incubated with 2 µg CrtM for 30 minutes at 20°C. The 
IC50 values were obtained by fitting the inhibition data to a normal doseresponse curve, using 
GraphPad PRISM® version 4.0 software for windows (GraphPad Software Inc., San Diego, CA, 
www.graphpad.com). Ki was calculated based on the IC50 value and the reported Km of CrtM 
(26). 
Staphyloxanthin biosynthesis inhibition assay  The S. aureus strain used was the WT clinical 
isolate (Pig1) (4). S. aureus was cultured in THB (1 mL) in the presence of inhibitor compounds 
for 72h, in duplicate. Cells were then centrifuged and washed twice with PBS. STX was 
extracted with MeOH and the O.D. was determined at 450 nm using a Perkin Elmer MBA 2000 
(Norwalk, CT) spectrophotometer. The IC50 values were obtained by fitting the O.D. data to a 
normal dose-response curve, using GraphPad PRISM®. 
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Human SQS enzyme expression, purification and inhibition assay  A DNA sequence 
encoding a double truncated protein lacking residues 31 at the N-terminus and 46 at the C-
terminus was amplified using the following primers : 5’ 
CATATGGACCAGGACTCGCTCAGCAGC and 3’ 
GGATCCTCAATTCTGCGTCCGGATGGT. The corresponding amplified insert was initially 
cloned in the vector pGEMT® (Promega). Plasmid was digested with the endonucleases NdeI 
and BamHI, and the resulting fragment was cloned into the bacterial expression vector pET-28a 
to give pET28a-HsSQS which was used to transform E.coli BL21 (DE3)RP strain (Novagen) for 
overexpression. This cloning procedure resulted in the addition of a six-histidine tag to the N-
terminus of doubletruncated HsSQS. 
Bacteria expressing the constructs were cultured in Luria-Bertani medium supplemented with 
kanamycin (30 µg/ml) and chloramphenicol (34 µg/ml) at 37ºC, until the cells reached an OD of 
0.4 at 600 nm, and were then induced at 37°C for 4 h by incubation with 1 mM isopropyl-1-thio-
β-D-galactopyranoside. Cells were harvested by centrifugation (10 min, 4000 rpm) and 
resuspended in 10 ml of lysis/elution buffer (20 mM NaH2PO3, pH 7.4, 10 mM CHAPS, 2 mM 
MgCl2, 10% glycerol, 10 mM - mercaptoethanol, 500 mM NaCl, 10 mM imidazole, and a 
protease inhibitor cocktail (Roche), disrupted by sonication, and centrifuged at 16,000 rpm for 30 
min. The supernatant (40 ml) was then applied to a HiTrap Nickel-Chelating HP column 
(Amersham Biosciences). Enzyme purification was performed according to the manufacturer's 
instructions using a Pharmacia FPLC system. Unbound protein was washed off with 50 mM 
imidazole, then the His6-HsSQS was eluted with 1M imidazole.  Purity was confirmed by SDS-
PAGE electrophoresis. Fractions containing the pure enzyme were pooled and dialyzed against 
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buffer A (25 mM sodium phosphate pH 7.4, 20 mM NaCl, 2 mM dithiothreitol, 1 mM EDTA, 
10% glycerol, 10% methanol), concentrated, then stored at -80°C. 
    SQS activity was based on measuring the conversion of [3H]FPP to [3H]squalene.  Final assay 
concentrations were 50 mM MOPS (pH 7.4), 20 mM MgCl2, 5 mM CHAPS, 1% Tween 80, 10 
mM DTT, 0.025 mg/mL BSA, 0.25 mM NADPH, and 7.5 ng of purified recombinant human 
SQS. The reaction was started with the addition of substrate (3HFPP, 0.1 nmol, 2.22x106 dpm) 
and the final volume of the reaction was 200 µL. After incubation at 37ºC for 5 min, 40 µL of 10 
M NaOH were added to stop the reaction, followed by 10 µL of a (100:1) mixture of 98% EtOH 
and squalene. The resulting mixtures were mixed vigorously by vortexing, then 10 µL aliquots 
were applied to 2.5 x 10 cm channels of a silica gel thin layer chromatogram, and newly formed 
squalene was separated from unreacted substrate by chromatography in toluene– EtOAc (9:1). 
The region of the squalene band was scraped and immersed in Hydrofluor liquid scintillation 
fluid, and assayed for radioactivity. IC50 values were calculated from the hyperbolic plot of 
percent of inhibition versus inhibitor concentration, using GraphPad PRISM®. 
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3.6 Tables and Figures 
Table 3.1  IC50 values of diphenylether phosphonosulfonates in CrtM inhibition. 
 
O P(O)(OK)2
SO3K
1
2
3
4
5
6
1'
2'
3'
4'
5'
6'
R1
R2  
 
 
Entry 
 
Compound 
 
R1 
 
R2 
CrtM IC50 
values (µM) 
1 1 H H 7.9 
2 5 4′-F H 2.3 
3 20 3′-F H 2.2 
4 21 2′-F H 6.9 
5 7 4′-CF3 H 7.2 
6 22 3′-CF3 H 9.8 
7 23 2′-CF3 H 53.7 
     
8 24 4′-Cl H 2.5 
9 6 4′-n-propyl H 2.2 
10 25 4′-tert-butyl H 10.5 
11 26 4′-CH2Ph H 13.5 
12 27 4′-OH H 28.2 
13 28 4′-OPh H 169.8 
14 29 4′-(furan-2-yl) H 26.3 
15 30 3′, 4′-2F H 1.7 
16 31 3′, 4′-2Cl H 2.2 
17 32 
O
3', 4'-
 
H 2.1 
18 33 3′, 5′-2F H 4.6 
19 34 3′, 5′-2Cl H 6.3 
     
20 35 4′-F 6-F 2.1 
21 36 4′-F 6-OCH3 81.3 
 
 
 
 
 66 
Table 3.2  CoMSIA results for CrtM inhibition. 
 
   CoMSIA pIC50 predictions 
 CrtM enzyme 
experimental 
activity 
   
test setsb 
compounda IC50 
(µM) 
pIC50 
(M) 
training 
set 
residual 1 2 3 4 5 
3 0.18 6.74 6.61 0.13 6.54 6.53 6.53 6.49 6.58 
2 0.48 6.32 6.55 -0.23 6.35 6.41 6.19 6.29 6.49 
30 1.7 5.76 5.62 0.14 5.61 5.60 5.56 5.55 5.70 
35 2.1 5.68 5.69 -0.01 5.69 5.41 5.51 5.58 5.76 
32 2.1 5.67 5.69 -0.02 5.65 5.46 5.44 5.54 5.49 
6 2.2 5.66 5.64 0.02 5.82 5.12 5.60 5.63 5.61 
20 2.2 5.66 5.34 0.32 5.33 5.32 5.29 5.25 5.41 
31 2.2 5.65 5.62 0.03 5.77 5.90 5.97 5.88 5.69 
5 2.3 5.63 5.44 0.19 5.45 5.34 5.32 5.37 5.48 
24 2.5 5.6 5.46 0.14 5.61 5.49 5.54 5.52 5.51 
33 4.6 5.34 5.37 -0.03 5.35 5.38 5.36 5.28 5.44 
4 5.4 5.27 5.21 0.06 5.09 5.13 4.87 5.06 5.23 
18 5.8 5.24 5.34 -0.10 5.28 5.10 5.20 5.22 5.32 
34 6.3 5.2 5.21 -0.01 5.24 5.47 5.54 5.40 5.23 
21 6.9 5.16 5.18 -0.02 5.16 5.01 5.03 5.04 5.25 
7 7.2 5.14 5.30 -0.16 5.59 5.33 5.51 5.47 5.32 
1 7.9 5.1 5.15 -0.05 5.15 5.05 5.03 5.05 5.18 
10 9.1 5.04 4.92 0.12 4.94 4.99 5.04 4.94 4.88 
22 9.8 5.01 5.05 -0.04 5.23 5.28 5.32 5.43 5.05 
25 10.5 4.98 5.10 -0.12 5.37 4.74 5.18 5.15 4.95 
26 13.5 4.87 4.91 -0.04 4.86 5.03 4.67 4.69 4.83 
17 20.4 4.69 4.72 -0.02 4.89 4.81 4.82 4.81 4.67 
9 21.9 4.66 4.73 -0.07 4.79 4.79 4.85 4.77 4.68 
11 24.5 4.61 4.75 -0.14 4.89 4.80 5.03 4.82 4.65 
29 26.3 4.58 4.71 -0.13 4.81 4.44 4.66 4.57 4.61 
27 28.2 4.55 4.55 0.00 4.55 4.55 4.55 4.55 4.55 
8 37.2 4.43 4.43 0.00 4.35 4.31 4.27 4.34 4.68 
16 43.7 4.36 4.36 0.00 4.36 4.36 4.80 4.36 4.36 
23 53.7 4.27 4.23 0.04 4.28 4.37 4.32 4.33 4.24 
12 72.4 4.14 4.15 -0.01 4.10 3.72 4.06 3.89 4.08 
36 81.3 4.09 4.16 -0.07 4.28 4.48 4.46 4.50 4.15 
13 123 3.91 3.86 0.05 3.91 4.16 4.08 4.12 3.84 
19 170 3.77 3.79 -0.02 3.91 4.09 3.92 4.07 3.70 
28 170 3.77 3.80 -0.03 3.90 3.85 3.96 4.20 3.82 
15 500 3.3 3.33 -0.03 3.24 3.25 3.12 3.20 3.40 
14 1700 2.77 2.65 0.12 2.53 2.65 2.50 2.56 2.71 
          
  r2 0.98  0.97 0.94 0.95 0.95 0.99 
  q2 0.72  0.69 0.71 0.72 0.67 0.70 
  F-test 245.8  151.6 82.4 113.9 97.5 280.1 
  N 7  6 5 4 5 7 
  n 36  31 31 31 31 31 
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Table 3.3 Staphyloxanthin inhibition in S. aureus. 
 
Compounda Staphyloxanthin 
IC50 (µM) 
Compounda Staphyloxanthin 
IC50 (µM) 
31 0.011 11 0.18 
33 0.015 10 0.18 
32 0.015 18 0.19 
8 0.019 20 0.22 
25 0.021 (R)-1 0.31 
24 0.039 9 0.35 
7 0.040 23 0.46 
26 0.049 13 0.49 
(S)-1 0.050 16 0.50 
34 0.051 21 0.51 
5 0.052 3 1.1 
35 0.059 29 1.1 
22 0.074 4 1.4 
6 0.093 2 2.2 
28 0.10 27 6.8 
1 0.11 36 13.8 
30 0.11 15 20.4 
12 0.16 14 33.9 
17 0.17 19 263 
 
               a Structures shown in Figures 3.2, 3.3 and Table 3.1. 
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Table 3.4 CoMSIA results for CrtM/hSQS selectivity. 
     CoMSIA predictionsd 
 Experimental data   test sets 
 
 
compound
a 
hSQS 
IC50 (µM) 
CrtM/hSQS 
selectivityb  
relative 
CrtM/hSQS 
selectivityc 
pIC50(CrtM) 
-pIC50(hSQS) 
(M) 
 
training 
set 
 
residual 
 
1 
 
2 
 
3 
 
4 
 
5 
6 1.9 0.85 295 -0.07 -0.16 0.09 -0.17 -0.18 -0.18 -0.16 -0.17 
25 4.0 0.38 132 -0.42 -0.38 -0.04 -0.28 -0.26 -0.31 -0.43 -0.27 
19 11.7 0.068 24.0 -1.16 -0.99 -0.17 -1.13 -1.15 -1.17 -0.97 -1.13 
26 0.72 0.054 18.6 -1.27 -1.29 0.02 -1.41 -1.40 -1.43 -1.29 -1.42 
7 0.17 0.024 8.3 -1.62 -1.52 -0.10 -1.51 -1.49 -1.53 -1.52 -1.51 
10 0.22 0.024 8.3 -1.62 -1.52 -0.10 -1.60 -1.45 -1.60 -1.51 -1.89 
29 0.54 0.021 7.1 -1.69 -1.70 0.01 -1.75 -1.73 -1.77 -1.71 -1.71 
30 0.033 0.019 6.6 -1.72 -2.12 0.40 -2.22 -2.21 -2.38 -2.09 -2.22 
27 0.47 0.016 5.8 -1.78 -2.34 0.56 -2.37 -2.39 -2.44 -2.34 -2.40 
9 0.35 0.016 5.6 -1.79 -1.98 0.19 -2.01 -1.81 -1.90 -2.00 -2.02 
13 1.8 0.015 5.1 -1.83 -1.93 0.10 -2.04 -2.01 -2.00 -1.90 -2.02 
3 0.003 0.014 4.8 -1.86 -2.00 0.14 -1.84 -1.80 -1.82 -1.99 -1.88 
4 0.072 0.014 4.7 -1.87 -1.93 0.06 -1.74 -1.71 -1.75 -1.97 -1.70 
11 0.29 0.012 4.1 -1.93 -1.64 -0.29 -1.62 -1.39 -1.50 -1.63 -1.64 
36 0.79 0.0098 3.4 -2.01 -1.88 -0.13 -1.97 -1.99 -2.00 -1.86 -1.95 
24 0.020 0.0079 2.8 -2.10 -2.15 0.05 -2.12 -2.12 -2.18 -2.09 -2.13 
18 0.042 0.0072 2.5 -2.14 -2.23 0.09 -2.30 -2.32 -2.30 -2.27 -2.38 
5 0.017 0.0071 2.5 -2.15 -2.29 0.14 -2.32 -2.33 -2.42 -2.29 -2.34 
33 0.032 0.0071 2.5 -2.15 -2.20 0.05 -2.33 -2.28 -2.34 -2.19 -2.30 
22 0.069 0.0071 2.5 -2.15 -2.31 0.16 -2.31 -2.31 -2.29 -2.47 -2.30 
28 1.1 0.0065 2.2 -2.19 -2.12 -0.07 -2.15 -2.16 -2.16 -2.12 -2.14 
31 0.014 0.0062 2.1 -2.21 -2.08 -0.13 -2.08 -2.06 -2.16 -1.99 -2.05 
20 0.008 0.0036 1.3 -2.44 -2.31 -0.13 -2.38 -2.35 -2.45 -2.31 -2.34 
17 0.069 0.0034 1.2 -2.47 -2.63 0.16 -2.54 -2.47 -2.47 -2.55 -2.56 
23 0.18 0.0033 1.1 -2.48 -2.48 0.00 -2.47 -2.49 -2.47 -2.53 -2.87 
34 0.020 0.0032 1.1 -2.49 -2.43 -0.06 -2.47 -2.40 -2.34 -2.41 -2.40 
1 0.023 0.0029 1.0 -2.54 -2.50 -0.04 -2.50 -2.49 -2.50 -2.52 -2.48 
14 3.7 0.0022 0.8 -2.66 -2.50 -0.16 -2.56 -2.58 -2.63 -2.51 -2.52 
2 0.001 0.0019 0.6 -2.73 -2.84 0.11 -2.66 -2.62 -2.62 -2.90 -2.60 
35 0.004 0.0018 0.6 -2.74 -2.65 -0.09 -2.62 -2.62 -2.67 -2.66 -2.61 
16 0.079 0.0018 0.6 -2.74 -2.68 -0.06 -2.78 -2.83 -2.77 -2.72 -2.82 
12 0.13 0.0018 0.6 -2.74 -2.70 -0.04 -2.74 -2.72 -2.76 -2.68 -2.74 
32 0.002 0.0011 0.4 -2.96 -2.60 -0.36 -2.51 -2.53 -2.55 -2.66 -2.55 
15 0.55 0.0011 0.4 -2.96 -2.92 -0.04 -2.91 -2.96 -2.96 -2.93 -2.89 
21 0.005 0.00073 0.3 -3.14 -2.78 -0.36 -2.75 -2.74 -2.77 -2.81 -2.74 
8 0.003 7.1E-05 0.02 -4.15 -4.16 0.01 -4.17 -4.16 -4.16 -4.18 -4.18 
            
    r2 0.94  0.93 0.93 0.94 0.95 0.92 
    q2 0.54  0.50 0.52 0.51 0.55 0.51 
    F-test 76.5  71.6 75.6 82.5 75.0 64.5 
    N 6  5 5 5 6 5 
    n 36  33 33 33 33 33 
aStructures shown in Figures 3.2, 3.3 and Table 3.1. bSelectivity = IC50(hSQS)/IC50(CrtM). cRelative selectivity = 
selectivity(compound)/selectivity(1). dBold values represent predicted activities of compounds that were not 
included in the training set. 
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Figure 3.1 (A) Pathway for staphyloxanthin biosynthesis (in S. aureus). (B) Pathway for 
cholesterol biosynthesis. Each biosynthetic pathway is thought to involve initial formation of 
presqualene diphosphate, catalyzed by CrtM (S. aureus) or squalene synthase. In the 
bacterium, the NADPH reduction step is absent, resulting in production of dehydrosqualene. 
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Figure 3.2 Structures of phosphonosulfonate and bisphosphonate compounds and their 
activities (IC50 values, µM, in parentheses) against dehydrosqualene synthase. 
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Figure 3.3 Structures of compounds and their activities (in parentheses) against 
dehydrosqualene synthase 
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Figure 3.4 Compound alignment and CoMSIA fields for CrtM inhibition. (A) Flexible 
alignment of compounds, only heavy atoms displayed for clarity; (B) steric fields, green 
favorable, red disfavored; (C) hydrophobic fields, magenta favorable, white disfavored; (D) 
electrostatic and H-bond donor fields; blue positive-charge favorable, yellow negative-charge 
favorable, cyan H-bond donor disfavored. 
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Figure 3.5 (A) Correlation between staphyloxanthin (cell) activity and CrtM (enzyme) activity, 
showing R2 = 0.27; (B) improved correlation between cell activity and enzyme activity with 
incorporation of a molecular descriptor, SlogP, with R2 = 0.60; (C) best cell activity prediction 
obtained by using CrtM inhibition plus two additional descriptors; R2 = 0.72 and Q2 = 0.62; (D) 
correlation between CrtM activity and human SQS activity, showing R2 = 0.50. 
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Figure 3.6 CoMSIA fields for CrtM/SQS selectivity. (A) steric fields, green favorable, red 
disfavored; (B) hydrophobic fields, magenta favorable, white disfavored; (C) electrostatic 
fields, blue positive-charge favorable. 
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Chapter 4 
Inhibition of Staphyloxanthin Virulence Factor 
Biosynthesis in Staphylococcus aureus by phosphono-
acetamides:  In vitro, In vivo and Crystallographic 
Results 
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4.2      Introduction 
 Infections caused by Staphylococcus aureus are a growing cause of concern (1, 2) due to 
the widespread development of antibiotic resistance and the shortfall in the introduction of new 
types of anti-infective agents.  An alternative strategy that is now gaining interest is targeting of 
bacterial virulence factors(3-5), molecules that are essential for bacterial growth and/or 
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invasiveness in vivo. Since these factors are by definition not essential for survival in vitro, 
screening for virulence factor inhibitors can be challenging. However, at least in the case of S. 
aureus (6, 7), one important virulence factor is a brightly colored carotenoid pigment, 
staphyloxanthin (STX), whose biosynthesis can be readily monitored spectrophotometrically. 
The carotenoid is produced by the condensation of the C15 isoprenoid farnesyl diphosphate (FPP) 
to form presqualene diphosphate and then dehydrosqualene, followed by a series of oxidations 
and glycosylations, in a series of reactions catalyzed by the enzymes CrtM, N, O, P…(8), and 
inhibition of these enzymes (e.g. CrtN by diphenylamine) has been known for many years to 
result in colorless bacteria (9, 10). In later work6, it was shown that loss of the STX pigment 
made S. aureus susceptible to killing by reactive oxygen species (ROS, such as H2O2, ClO-, OH) 
produced by neutrophils, blocking infectivity. Consequently, inhibition of staphyloxanthin 
biosynthesis is a potential novel target of anti-infective therapy against pigmented S. aureus 
strains (11-13). 
The first committed step in staphyloxanthin biosynthesis (Figure 3.1) involves the 
condensation of two FPP molecules to form dehydrosqualene.  This reaction is thought to occur 
via a presqualene diphosphate intermediate and is very similar (or identical) to that catalyzed by 
squalene synthase (SQS) in plants, animals, and some protozoa, where the squalene so produced 
is then converted into sterols such as cholesterol, ergosterol, and the plant sterols.  It was thus of 
interest to see if any of the many known SQS inhibitors previously developed as cholesterol 
lowering drug leads might also have activity in blocking staphyloxanthin biosynthesis, and hence 
S. aureus virulence. We recently reported that one class of inhibitor, phosphonosulfonates, did 
exhibit such activity (14).  The phosphonosulfonates (and related bisphosphonates) were 
developed earlier on by Magnin, Biller et al. (15, 16) using FPP as a “template”. The 
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bisphosphonate analogs of FPP tended to bind to bone and also caused elevation of liver enzyme 
function, and the farnesyl side-chain was metabolically reactive.  However, the 
phosphonosulfonates did not have these drawbacks, and replacement of the farnesyl side-chain 
by a diphenyl ether removed the metabolic instability. Using 1: 
HO P
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O S
HO
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PHO
OH
O
S
OH
O
O
OH
P OHO
S
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O
1 32  
we found good CrtM inhibition restored ROS (H2O2, neutrophil) sensitivity, and importantly,  
observed with a major decrease in bacterial burden following S. aureus challenge, in mice (14).  
There are, however,many other conceivable backbones (as well as side-chains) that might also 
have good or even better activity.  To explore some of these possibilities, we were particularly 
interested to see if it might be possible to reduce backbone charge/acidity/polarity while still 
retaining CrtM activity, since this might improve inhibitor uptake into bacterial and host cells, as 
well as further reducing bone-affinity.  The possibility that less polar analogs might still have 
good activity is supported by the observation that, unlike bisphosphonate inhibitors of farnesyl 
diphosphate synthase (FPPS), our published CrtM results indicated that Mg2+-binding (which 
usually involves binding to two anionic groups) is not essential for potent phosphonosulfonate 
inhibition of CrtM (14).  For example, while 1 binds to CrtM with 2 Mg2+ (PDB file 2ZCQ), 2 
binds with only 1 Mg2+ (PDB file 2ZCR), and 3 has no Mg2+ at all in its x-ray crystallographic 
structure (PDB file 2ZCS).  So, unlike the situation found with FPPS, it seemed likely that a 
broad range of backbone structures having fewer anionic groups might be developed, since the 
number of metal ions involved in binding to CrtM is quite variable.   
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         In this work, we describe the synthesis of, and inhibition by, 18 compounds encompassing 
the 11 basic structural motifs (a-k) shown in Figure 4.1 in which Ar = an aromatic fragment. 
Since some compounds were prepared as salts while others were free acids, these motifs are 
shown for simplicity in their protonated or free acid forms, a point we discuss later in the Text.  
These motifs were designed based on the following ideas:  In a, we reduced the (potentially) -3 
formal side-chain charge found in the phosphonosulfonates (-PO3H2/-PO32-; -SO3H/-SO3-) to -2, 
but added a H-bond donor/acceptor amide site, a feature suggested at least in part because of 
synthetic accessibility. In all cases, the number of methylene groups n in the “spacer” (Figure 
4.1) was in the range n=2-4, typically n = 3, and the Ar groups were diphenyl ethers or biphenyls.  
In b and c we reduced the side-chain formal charge to -1, but of course the sulfonic and 
carboxylic acids are expected to have very different pKa values.  In d and e we investigated 
whether methyl substitutions might affect activity, while in f we investigated the effect of 
modifying H-bond donor ability.  In g-i we further investigated the role of H-bonding while in j, 
we attempted to design a novel motif that might facilitate metal binding. Finally, compound k (a 
phosphinomethylphosphonate) was included as a non-hydrolysable diphosphate analog 
(replacing two -O- linkages with two -CH2-).  We also report the x-ray crystallographic structure 
of one of the most potent CrtM/STX biosynthesis inhibitors (containing motif a) bound to CrtM, 
which gives interesting new insights into how this compound binds to its CrtM target. 
 
4.3      Results and Discussion 
We synthesized a total of 18 compounds (4-21) based on the 11 motifs shown in Figure 
4.1 and the structures of these compounds are shown in Table 4.1, rank ordered in terms of 
decreasing activity in CrtM inhibition.  The Ki values were determined by using a coupled 
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diphosphate /phosphate release assay (17), as described in the Experimental Section, and are also 
reported in Table 4.1.  As can be seen in Table 4.1, the most potent inhibitors (4-6) were all 
diphenyl ether phosphonoacetamides (motif a, Figure 4.1) containing a (CH2)3 spacer between 
the aromatic and amide moiety, and had Ki values in the range 30-70 nM, slightly greater than 
the 20 nM found for the lead phosphonsulfonate 1 in the same assay.  The activity of these three 
compounds in the inhibition of STX biosynthesis in S. aureus are also shown in Table 4.1, from 
which we see that 5 is the most active compound in this bacterial cell-based assay, with an IC50 
of 8 nM, much less than the IC50 of ~100 nM reported for 1, due presumably to improved 
cellular uptake. Substitution of 1 and 2 Cl atoms on the diphenyl ether side-chain had relatively 
little effect on CrtM inhibition, but decreased bacterial STX production by ~3-5x (with respect to 
5), Table 4.1.  Shortening the (CH2)n spacer by 1 CH2 group (14) decreased activity in both 
assays (CrtM ~40x; STX ~400x) while lengthening the spacer by 1 CH2 group (16) had an even 
larger effect (CrtM IC50  ~130x, STX ~400x, again versus 5).  We also found that replacing the 
diphenyl ether side-chain by a biphenyl group (10) reduced both CrtM inhibition (by ~20x) and 
STX biosynthesis (~600x), Table 4.1.  So, the diphenyl ethers containing a (CH2)3 spacer had 
most activity, both in the enzyme as well as in the whole bacterial cell assays. 
We next investigated the effects of changing the PO3H2 group to a SO3H group (Figure 
4.1 motif b) or a –CO2H group (Figure 4.1, motif c).  The sulfonoacetamide (11) had weak 
activity in both assays:  a Ki = 0.81 µM in CrtM inhibition (~20x higher than 5) and an IC50 = 15 
µM in STX biosynthesis inhibition (~600x higher than 5), Table 4.1.  The results obtained with 
the carboxylic acid analog (21) in which the –PO3H group was replaced with a –CO2H group 
were even worse, with a Ki > 7 µM and an IC50 (STX) of 200 µM, ~200x and ~25,000x worse 
than with the phosphonoacetamide 5, Table 4.1. So, the ordering of activity is -PO3H2/-PO32- > -
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SO3H/-SO3- >> -CO2H/-CO2- in both CrtM and STX biosynthesis inhibition, suggesting the 
likely importance of multiple electrostatic interactions (and/or H-bonding) between CrtM and the 
inhibitor’s anionic group.  Also of interest is the observation that, at least for the compounds 
where Ki values are accurately known (i.e. they are not limit values, Table 4.1), the cell-based 
activity values cover a larger range than do the CrtM enzyme inhibition results, suggesting 
perhaps the importance of variations in bacterial cell uptake between the different inhibitors.   
Based on these observations, we next investigated the effects of methyl substitutions on 
activity.  In the case of the d motif, dimethyl substitution on the acetamide CH2 (13) would 
increase hydrophobicity, but this compound had worse CrtM activity (
 
!
>  20x) and much worse 
(
 
!
>  62,500x versus 5) activity in STX biosynthesis, where it was essentially inactive (IC50 ~0.5 
mM, Table 4.1). In the case of the N-Me substituent (Figure 4.1, motif e), the single methyl 
group on nitrogen (12) reduced activity by a factor of ~20x versus 5 (to a Ki = 0.91 µM) – 
essentially the same as that seen with the dimethyl analog (13), but in contrast to 13, there was 
still measurable STX inhibition activity (IC50 = 8.6 µM, ~1000x worse than with 5).  That is, the 
N-Me (12) and C(Me)2 (13) analogs have essentially the same activity in CrtM inhibition (0.91 
µM, 0.96 µM, respectively) while STX biosynthesis inhibition is very different (8.6 µM, >500 
µM, for 12 and 13, respectively),  supporting again the idea that the -COCH2PO3H2 group is 
important for cell-based activity.  These results also suggested to us that the amide NH group 
might be important in hydrogen bonding to the protein, since the NH to NMe substitution 
reduced CrtM activity by ~20x (Table 4.1).  
 Given the apparent importance of this region for activity, it was of interest to see if 
activity might be improved by conversion of the NHCO amide moiety to a hydroxamate 
(NOH•CO, Figure 4.1, motif f), which would provide alternative possibilities for H-bond 
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formation. We made three hydroxamates, 8, 9 and 20, the first two species containing diphenyl 
ether sidechains, the third, a biphenyl. Interestingly, both the dichloro and unsubstituted diphenyl 
ether phosphonohydroxamates had good activity in both CrtM and STX biosynthesis inhibition 
(Table 4.1), although they were both less active than the three most potent phosphonoacetamides.  
On average, the hydroxamates were ~6x less active against CrtM and ~2x less active in the STX 
biosynthesis assay, Table 4.1.  Not unexpectedly, the biphenyl hydroxamate (20) was even less 
active, consistent with the weaker activity of the biphenyl phosphonoacetamide, 10.  So, for 
activity, these results indicate the importance of a phosphonoacetyl group, located in either an 
acetamide or a hydroxamate group, suggesting the importance of both electrostatic (H-bond) 
interactions between the phosphonate and the protein and, most likely, hydrogen bonding 
between the amide (or hydroxamate) and the protein.  To test these ideas further, we next 
investigated motifs g-i, Figure 4.1, using compounds 19, 17 and 18.  Surprisingly, the 
sulfonamide 19 had no activity in either the CrtM or STX biosynthesis assay (Table 4.1), 
suggesting a critical role for the amide/hydroxamate CO group as an H-bond acceptor.  
Consistent with this, neither the ester (17) nor the ketone (18) had significant activity in either 
assay, Table 4.1. 
We then investigated two additional motifs, j and k in Figure 4.1.  The hydroxamate (j, 
15) had modest activity in both assays (Ki, IC50 ~4 µM) but was ~100x (CrtM) to ~500x (STX) 
less active than was 5. The phosphinomethylphosphonate 7 (motif k) was a potent CrtM inhibitor 
(Ki = 220 nM), but again we believe due to its increased polarity, was ~50x less effective in STX 
biosynthesis inhibition in whole cells than was the most potent phosphonoacetamide (5). 
Finally, we investigated the effects of all 18 compounds on human SQS inhibition, 
together with their activity in growth inhibition of three human tumor cell lines (MCF-7, NCI-
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460 and SF-268), Table 4.1.  Although inhibition of human SQS may not be a particularly 
important toxicologic consideration, given a choice it would seem to be preferable to have a STX 
biosynthesis inhibitor with poor activity against SQS, as opposed to one with potent SQS activity, 
and as can be seen in Table 4.1, several potent CrtM inhibitors do have relatively little activity in 
the SQS assay.   More important, in essentially all cases we find no inhibition of human cell 
growth (in three human cell lines, IC50 > 300 µM), supporting the idea that these compounds will 
have low toxicity.  In fact, only the ester 17 had significant activity (IC50 ~70-90 µM) on human 
cell growth, but since this compound is inactive in STX biosynthesis inhibition, it is not likely to 
be of interest. 
Structure and Structure-Function Aspects The results described above are of interest since 
they represent the development of several new, chemically diverse, anti-virulence inhibitors for S. 
aureus.  However, the relationships between structure and activity need to be explored in more 
detail in order to obtain a better understanding of how, in particular, the most active compounds 
act on their CrtM target.  What is interesting about the most active compounds, the 
phosphonoacetamides, is that while they contain the same 3-(3-phenoxyphenyl)propyl  
(PhOC6H4(CH2)3-) side-chain as found in the most active phosphonosulfonates18, the “backbone” 
is clearly ~2 bond lengths greater in the new compounds. So we next examined the effects of this 
common feature on binding. 
               In the CrtM enzyme, there are two binding sites for FPP14 and in previous work we 
found that phosphonosulfonates could bind to either one of these sites14.  The diphenyl ether 
phosphonosulfonate 1 bound to site-1 and had interactions with 2 Mg2+, while two biphenyl 
phosphonosulfonates (2, 3) bound to site-2, with 1 and 0 Mg2+, respectively.  This observation 
complicates any QSAR analysis since there could be 0, 1 or 2 Mg2+ present, and two different 
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sites might be occupied.  Plus, with the phosphonoacetamides, the presence of a longer backbone 
complicates the situation further since e.g. if the diphenyl ether is located in the same region as 
found with 1, the head-group will not fit.  We therefore next obtained the structure of a CrtM-5 
complex using x-ray crystallography, to determine how 5 does in fact bind to CrtM, in order to 
provide a better, albeit qualitative, structure-based interpretation of the activity of one of the 
most potent inhibitors. Data collection and refinement statistics are given in Table 4.2 and full 
details are given in the Experimental Section.  
                 CrtM crystallizes in the P3221 space group and there is one molecule per asymmetric 
unit.  The phosphonoacetamide 5 yielded well-resolved 2Fobs – Fcalc densities (Figure 4.2A) and 
the refined structure of 5 (red) is shown superimposed on FsPP (bound to CrtM) in Figure 4.2B 
and on 1-3 in Figure 4.2C. Interestingly, 5 binds to CrtM in a completely different manner to that 
observed with FsPP or any of the three phosphonosulfonates reported previously14. Its polar 
phosphonate head-group is located in the FsPP site-1, where it makes a salt bridge with Arg45 
and H-bond contacts with Gln165 and Asn168, together with a complex H-bond network with 5 
H2O molecules, Figure 4.3A. However, unlike the situation found with 1, the diphenyl ether 
side-chain occupies the FPP site-2.   In addition, the amide CO forms H-bonds with Arg45 and 
two H2O molecules, and the amide NH acts as an H-bond donor to Gln165, Figure 4.3B. 
Basically, then, Essentially, the increased length of 5 (over that present in the 
phosphonosulfonates) is accommodated in the protein by 5 “bridging” both the S1 and S2 
binding sites (Chapter 2), Figure 4.2B,C 
Given this new structure (PDB 2ZY1), it is now possible to rationalize several of the 
SAR observations noted above.  Specifically, conversion of the –PO32- group in 5 to –SO3- or –
CO2- can be expected to result in the loss of many of the H-bond/electrostatic interactions with 
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Arg45, Gln165 and Asn168, and the 5 H2O molecules.  Second, conversion of the amide NH to 
NMe will prevent H-bond formation with Gln165, as will formation of an ester (17) or a ketone 
(18) in this region.  Likewise, conversion of the amide to the hydroxamate (9) results in 
disruption of this H-bond interaction which may, however, be partially compensated for by other 
conformational changes, since 9 still retains quite good (Ki = 320 nM) CrtM activity. But how 
can we correlate our enzyme inhibition results with cell based inhibition of STX biosynthesis, 
something that is clearly desirable since we are interested in good inhibition of virulence factor 
formation in cells, and not just good CrtM inhibitors (which might not actually get into cells). 
In Vitro and In Vivo Results  When considering all compounds investigated, we find that there 
is quite a good correlation between the CrtM enzyme pKi (= -log10 Ki, M) and cell STX 
biosynthesis inhibition pIC50 (= -log10 IC50, M) values, as can be seen in Figure 4.4A where the 
R2 value is 0.73 (for the 14 compounds having non-limit Ki/IC50 values).  However, when we 
add results for the 38 compounds reported previously to the correlation, the n=52 compound data 
set exhibits a much worse correlation (Figure 4.4B) with an R2=0.42. This is similar to the results 
we reported previously where we found for 10 different enzyme/cell assays that on average the 
R2 value for the pKi/pIC50 correlation was only 0.32 (ref. 19) making, of course, any predictions 
of cell-based activity based on enzyme activity in some cases, impossible.  The large 
discrepancies found were, we proposed, likely to be due to the neglect of factors that affect 
inhibitor uptake into cells, and we described a general method in which this aspect might be 
taken into consideration, by using a “combinatorial descriptor approach”19.  That is, we described 
cell activity by using the following equation: 
                                  pIC50 (cell) = a•pKi (enzyme) + b•B + c•C + d 
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where a-d are linear regression coefficients and B,C are mathematical descriptors (such as SlogP) 
chosen in a combinatorial manner from a large series of potential descriptors (such as the 230 
descriptors in the program MOE (20). Applying this same method to the combined data set (52 
compounds) we now obtain (Figure 4.4C) an R2 = 0.69, a significant improvement. 
To investigate in vivo activity, we selected the most potent in vitro STX biosynthesis 
inhibitor (5), and carried out an intra-peritoneal challenge experiment in exactly the same manner 
as reported previously for 114.  We treated one group of mice (n = 9) with 0.5 mg of 5 twice per 
day (days -1, 0, 1, and 2), and a second group (n = 9) with equivalent volume injections of PBS  
control.  Upon sacrificing the mice at 72 hours, S. aureus bacterial counts in the kidneys of the 
mice treated with 5 were significantly lower than those of the control group (p < 0.001).  The 
median number of colony forming units (cfu) in the untreated animals was 22,500 cfu/mL to be 
compared with 850 cfu/mL for the treated animals, Figure 4.5, about a 96% reduction in 
surviving bacteria in the treatment group. 
 
4.4     Conclusions 
 The results we have described here are of interest for a number of reasons.  First, we have 
synthesized a broad variety of inhibitors of the dehydrosqualene synthase enzyme, CrtM, 
exhibiting novel structural motifs.  Second, we have determined their activity in CrtM inhibition 
and in staphyloxanthin biosynthesis in S. aureus.  Third, we show that STX biosynthesis activity 
for a broad range of inhibitors can be predicted from enzyme inhibition results with quite good 
R2 values by using a combinatorial descriptor approach.  Fourth, we have demonstrated that the 
most potent STX biosynthesis inhibitor in vitro also has activity in vivo in preventing infection.  
Fifth, we show that these compounds have no activity against three human cell lines. Sixth, we 
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have obtained the x-ray crystallographic structure of the most potent STX biosynthesis inhibitor 
investigated here (5) bound to CrtM.  The structure is unusual in that the inhibitor actually 
bridges the S1 and S1 sites observed previously14, whereas the phosphonosulfonates reported 
previously bind to one or other of these sites, but not to both.  Many of the major changes in 
CrtM activity between the different motifs investigated can be interpreted in terms of the 
crystallographic results, opening up the way to the further development of this class of 
compound as novel anti-infective agents targeting inhibition of the biosynthesis of the 
staphyloxanthin virulence factor in S. aureus. 
 
4.5      Materials and Methods 
CrtM expression and purification, CrtM inhibition assay, Staphyloxanthin biosynthesis inhibition 
assay, human SQS enzyme expression, purification and inhibition assay are described in the 
Chapter 3.   
Human cell growth inhibition assay  Three human cell lines MCF-7, NCI-H460  and SF-268 
were obtained from the National Cancer Institute.  Cells were cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum and 2 mM L-glutamine at 37°C in a 5% CO2 
atmosphere with 100% humidity. A broth micro-dilution method was used to calculate IC50 
values for growth inhibition by each compound. Cells were inoculated at a density of 5,000 
cells/well into 96-well flat bottom culture plates containing 10 µL of the test compound, 
previously half-log serial diluted (from 0.316 mM to 0.1 pM) for a final volume of 100 µL.  
Plates were then incubated for 4 days at 37°C in a 5% CO2 atmosphere at 100% humidity after 
which an MTT ((3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) cell 
proliferation assay (ATCC, Manassas, VA) was used to quantify cell viability. The IC50 values 
 91 
were obtained by fitting the O.D. data to a normal dose-response curve, using GraphPad 
PRISM®.   
Murine model of kidney infection 10 to 12 wk old CD1 male mice (Charles River Laboratory) 
were randomized into two groups at the start of the experiment and administered either 0.5 mg of 
BPH-652 or PBS control, i.p., twice a day, starting on d-1 to d2 (a total of 8 doses).  All mice 
were injected intraperitoneally (i.p) with 108 early stationary phase S. aureus on d0 .  After 3d, 
animals were euthanized, kidneys homogenized in PBS, and plated on THA for quantitative 
bacterial culture. 
Statistics The significance of experimental differences in the mouse in vivo challenge studies 
were evaluated by use of the two-tailed Student’s t test. 
X-Ray Crystallography Native CrtM was eluted from Ni-NTA beads by incubation with Factor 
Xa (Novagen) to cleave it from the polyhistidine-containing N-terminal thioredoxin fusion tag. 
The cleaved product was equilibrated with buffer containing 150 mM NaCl, 5 mM DTT, 1 mM 
β-mercaptoethanol, 5 % glycerol and 20 mM Tris pH 7.5, and then concentrated to 15 mg/ml.  
Native CrtM crystals (space group P3221) were grown using the hanging-drop method by mixing 
equal amounts of reservoir with 0.12-0.58 M potassium sodium tartrate, at room temperature. 
BPH-830 was incorporated by soaking crystals with a solution of 5 (10 mM in DMSO) for 3 
hours at RT. X-ray diffraction data were collected at SPXF beamline BL13B1 at the National 
Synchrotron Radiation Research Center (NSRRC), Hsinchu, Taiwan. All diffraction images were 
recorded using an ADSD Q210 CCD detector, and the data were indexed, integrated and scaled 
by using the HKL2000 package (21). The structure of the CrtM-5 complex was determined by 
molecular replacement using CNS (22) using the refined native CrtM (PDB 2ZCO) as a search 
model. Iterative cycles of model building with Xtalview (23) and computational refinement with 
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CNS were performed, in which 5% reflections were set aside for Rfree calculation (24). The 
stereochemical quality was assessed with the program PROCHECK (25). Figures were obtained 
by using Pymol (26). 
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4.6 Tables and Figures 
Table 4.1 Enzyme (CrtM, Ki), pigment (STX, S. aureus, IC50) and cell growth (IC50) inhibition 
results for 4-21. 
Compound  Structure CrtMa Ki 
(μM) 
STXb 
(S. 
aureus) 
(μM) 
hSQSc 
Ki 
(μM) 
MCF-7 
cellsd 
(μM) 
NCI-
H460 
cellse 
(μM) 
SF-
268 
cellsf 
(μM) 
4 
O
N
H
O
P(O)(OK)2Cl
Cl
 
0.03 0.04 0.74 >300 >300 >300 
5 
O
N
H
O
P(O)(OK)2
 
0.04 0.008 0.53 >300 >300 >300 
6 
O
N
H
O
P(O)(OK)2
Cl  
0.07 0.028 1.1 >300 >300 >300 
7 
O P
O
P(O)(OK)2
OK  
0.22 0.44 >30 >300 >300 >300 
8 
O
N
O
P(O)(OK)2
Cl
Cl
OH  
0.32 0.042 1.6 >300 >300 >300 
9 
O
N
OH
O
P(O)(OK)2
 
0.32 0.11 30 >300 >300 >300 
10 
N
H
O
P(O)(OH)2
 
0.81 5.0 >30 >300 >300 >300 
11 
O
N
H
O
SO3H
 
0.81 15 >30 >300 >300 >300 
12 
O
N
O
P(O)(OK)2
 
0.91 8.6 1.0 >300 >300 >300 
13 
O
N
H
O
P(O)(OK)2
 
0.96 >500 0.52 >300 >300 >300 
14 O HN
O
P(O)(OK)2
 
1.5 3.0 6.2 >300 >300 >300 
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Table 4.1 (continue) 
 
15 O P(O)(OK)2
CONHOH  
4.1 4.2 0.30 >300 >300 >300 
16 O HN
O
P(O)(OK)2
 
5.3 35 >30 >300 >300 >300 
17 
O
O
O
P(O)(OK)2
 
5.7 >500 >30 69 67 86 
18 
O
O
P(O)(OK)2
 
>7.0 28 20 135 130 191 
19 
O
N
H
S
O
O
P(O)(OK)2
 
>7.0 >500 >30 >300 >300 >300 
20 
N
O
P(O)(OH)2
OH
 
>7.0 4.1 >30 266 229 284 
21 
O
N
H
O
COOK
 
>7.0 200 >30 283 306 306 
a The value given are the Ki values for CrtM inhibition, in µM. 
b The values given are the IC50 values for STX (staphyloxanthin) virulence factor inhibition in S.   
  aureus and are in µM. 
c The values given are the Ki values for human squalene synthase inhibition (in vitro) and are  
  in µM. 
d The values given are the IC50 values for MCF-7 cell growth inhibition, in µM. 
e The values given are the IC50 values for NCI-H460 cell growth inhibition, in µM. 
f The values given are the IC50 values for SF-268 cell growth inhibition, in µM. 
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Table 4.2 Data collection and refinement statistics for CrtM•5 Complex 
 
Crystal CrtM•5 
Data Collection 
Radiation source NSRRC BL13B1 
Wavelength (Å) 1.00000 
Space group P3221 
Unit cell dimensions 
a (Å) 80.59 
b (Å) 80.59 
c (Å) 90.02 
Resolution (Å)a 30-1.78 (1.84-1.78) 
No. of reflections 32804 (3224) 
Completeness (%) 99.7 (100) 
Redundancy 6.3 (6.2) 
Rmerge (%) 2.6 (33.1) 
I/s(I) 51.7 (4.6) 
Refinement 
No. of reflections 31532 (2840) 
Rwork (%) 18.2 (22.9) 
Rfree (%) 21.9 (23.7) 
Geometry deviations 
Bond lengths (Å) 0.015 
Bond angles (°) 1.6 
Mean B-values (Å2) / No. 
Protein atoms 29.5 / 2353 
Compound atoms 29.2 / 24 
Water molecules 53.1 / 507 
Ramachandran plot (%) 
Most favored 93.9 
Additionally 
allowed 6.1 
aValues in the parentheses are for the highest resolution shells. 
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Figure 4.1  Structural motifs present in the different inhibitors investigated. 
 
 
 
Figure 4.2  X-ray crystallographic results. A, 2Fo-Fc electron density for 5 in CrtM; B, 
superposition of 5 (red) in the CrtM active site (2ZY1) with that of two molecules (green, 
yellow) of S-thiolo-farnesyl diphosphate (2ZCP); C, superposition of 5 (red) with 1 (blue), 2 
(yellow), 3 (cyan) in the CrtM active site (2ZCQ, 2ZCR, 2ZCS). 
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Figure 4.3 Interactions between 5 and different residues in the CrtM active site. A, Pymol (26) 
view; B, Ligplot (27) interactions. 
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Figure 4.4 showing correlations between CrtM inhibition and STX biosynthesis inhibition. A, 
data for the 14 compounds reported in this work; B, combination of 38 phosphonosulfonate 
inhibitor results (18) with the 14 compounds reported here; C, combinatorial descriptor search 
result for all 52 compounds tested (here and in ref. 18) in CrtM and STX biosynthesis inhibition. 
The lower R2 value in B is likely due the high diversity of the large data set; the R2 improves to 
0.69 by using the combinatorial descriptor approach (19). 
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Fig 4.5 In vivo results showing ~96% reduction in S. aureus colony forming in mice receiving 
treatment with 5. 
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Chapter 5 
Non-phosphonate Inhibitors of Dehydrosqualene 
Synthase and Staphyloxanthin Virulence Factor 
Biosynthesis 
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5.2   Introduction 
With the ever-increasing rise in drug resistance [1, 2], there is currently considerable interest in 
the development of novel anti-infectives that target bacterial virulence factor formation [1, 3, 4].  
In the case of Staphylococcus aureus [5, 6], a major virulence factor is the golden carotenoid 
pigment staphyloxanthin, STX.  This pigment is thought to act as a protective shield for the 
organism by blocking reactive oxygen species (e.g. H2O2, ClO-, OH) from neutrophils which are 
 
105 
thought to be detoxified by interacting with the polyene side-chain.  The first step in STX 
biosynthesis [6] involves the head-to-head condensation of two farnesyl diphosphate molecules 
and is catalyzed by the enzyme dehydrosqualene synthase (CrtM).  Knocking-out the CrtM gene 
in S. aureus does not affect bacterial cell growth in vitro [5], but the bacteria are white and are 
non-infective, in mice, since they lack the protection shield.  The same effect can be achieved by 
chemically inhibiting the CrtM enzyme and in previous work [7] we found that two classes of 
compounds, bisphosphonates and phosphonosulfonates, were good CrtM inhibitors, and that the 
latter compounds blocked pigment formation in cells [7], in addition to making bacteria 
susceptible to ROS-based killing in vitro, as well as innate immune system clearance in mice [7].  
These phosphonosulfonates were originally developed [8] as leads for cholesterol lowering drugs 
that inhibit the human analog of CrtM, squalene synthase (SQS), with both CrtM and SQS 
catalyzing formation of the C30 isoprenoid pre-squalene diphosphate, Figure 3.1, the first 
committed step in sterol and carotenoid biosynthesis.  Phosphonosulfonates (and 
bisphosphonates) are, however, expected to have only modest cell permeability and oral 
availability [9], so it is of interest to discover new scaffolds and structures.  Here, we report 
recent progress in the discovery of “phosphonate-free” CrtM inhibitors using two approaches: a 
“rational” approach, based on analogs to other enzymes that contain Mg2+/Asp-rich catalytic 
centers, and high throughput screening. 
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5.3   Results and Discussion 
A rational approach based on HIV-1 integrase inhibitors  The active site of CrtM contains 
two Asp-rich repeats: a DDXXD domain and a DXXXD domain, which bind to Mg2+ which 
catalyzes ionization of the substrate farnesyl diphosphate as well as the intermediate, presqualene 
diphosphate [10].  In HIV-1 integrase, there is a DDXSE domain thought to be involved in Mg2+ 
binding, and catalysis, and this suggested the possibility that HIV-1 intergrase inhibitors that 
bind to Mg2+ might serve as leads for CrtM inhibitors, by also binding to the Asp-rich repeats, 
via Mg2+. 
 To test this hypothesis, we produced four inhibitors, (1-4), Figure 5.1.  In Figure 5.1A we 
show a schematic illustration of how Mg2+ binds to the diketo acid moiety in an HIV-1 integrase 
inhibitor [11] in which Mg2+ are thought to interact with the carboxylate group, the enolate 
oxygen, and the ketone group.  We made two diketo-acids, 1 (BPH-1034), and 2 (BPH-1091), 
both of which contain the biphenyl ether present in the most potent phosphonosulfonate CrtM 
inhibitiors [12] and binds to the S1, allylic binding site in CrtM, as well as in SQS [10].  Both 
compounds inhibited CrtM with Ki ~ 250 nM, plus they also blocked STX pigment formation in 
cells (1, BPH-1034 IC50 = 4 µM). 
 The second class of potential inhibitors, Figure 5.1B, were based on the 
dihydroquinoline-3-carboxylic acid HIV-1 integrase inhibitor [13], which as with the diketo 
acids (or hydroxyacrylates), are thought to bind to the carboxyl, carbonyl and enolate oxygens.  
We again made two potential inhibitors (3, 4), but this time we synthesized alkoxylaryl species 
that, based on Glide [14] docking, seemed likely to bind in the S2, homoallylic site [10].  The 
longer chain species 4 had no activity, but the shorter chain species 3 (BPH-1112) had a CrtM Ki 
= 430 nM [and cell activity/ADD].  We then attempted co-crystallization (and soaking) of all 4 
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inhibitor leads, and obtained crystals of CrtM + 1 (BPH-1034) and CrtM + 3 (BPH-1112), which 
diffracted to 2.3 and 1.91Å, respectively.  Full x-ray crystallographic data and structure 
refinement details are given in Table 5.1. 
 We show in Figure 5.2 the crystallographic results for the diketo-acid complex, 1(BPH-
1034).  The diphenyl ether fragment binds into the S1 site, as anticipated, Figure 5.2A, and is 
superimposed on the two substrate-analog inhibitors, S-thiolo-farnesyl diphosphate (in green, 
yellow), whose structure was reported previously [7].  The diphenyl ether sidechain also has only 
a 0.7Å rmsd from the diphenyether sidechain in the phosphonosulfonate, BPH-652 [7], as shown 
in Figure 5.2B.  There is, therefore, clearly a preference for this “bent” sidechain to bind into the 
S1 site, while biphenyl-containing inhibitors prefer to bind to S2 [7].  The diketo acid backbone 
interacts with two of the three Mg2+ seen in the CrtM-FSPP structure (Mg2+B and Mg2+C, using 
the nomenclature adopted for other prenyl synthases, [15]).  What was unexpected about the 
structure is that CrtM actually co-crystallized with an additional molecule, farnesyl 
monophosphate (shown in magenta in Figure 5.2A, C) with the farnesyl sidechain having a 0.8Å 
rmsd from the S2 FSPP reported previously [7].  The 2Fo-Fc electron densities (contoured to 1.0 
σ, grey and 2.0 σ, red) for both 1 (BPH-1034) as well as farnesyl phosphate are shown in Figures 
5.3, the identity of farnesyl monophosphate being confirmed by using LC-MS (Figure 5.4). 
 In the case of the 1,2-dihydro-4-hydroxy-2-oxo-pyridine-3 carboxylic acid, 3 (BPH-
1112), the crystallographic results (Figure 5.5A, electron density in Figure 5.3B) show that in 
this case, the long n-alkyloxyaryl sidechain binds in the homoallylic, S2 or “straight sidechain” 
site, and that the alkyloxy group is located in a very similar position to that occupied by the 
farnesyl sidechain in the FSPP (and FP) structures.  There are 3 Mg2+ in the x-ray structure, 
Figure 5.5B.  However, these are not Mg2+ABC but rather Mg2+BCD: that is, there is a new Mg2+ 
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binding site.  The dihydropyridine side-chain interacts with Mg2+CD but surprisingly, via the two 
ring oxygens and not the carboxylate, which interacts with two water molecules, Figure 5.5C.  
           Of the two classes of inhibitors investigated here, the diketo acids appear more promising 
since as shown in Table 5.2, they have little activity against 3 human cell lines (MCF-7, SF-268 
and NCI-H460), while the dihydropyridines have quite potent human cell growth inhibition 
activity (IC50 ≈ 4 µM) – although this could make them of interest in other contexts. 
In silico High Throughput Screening and Similarity Search Based Leads  We next carried 
out an in silico HTS search for other CrtM inhibitor leads.  We used the CrtM-BPH-652 structure 
reported previously ([7], PDB ID code 2ZCQ) but minus the phosphonosulfonate ligand, but 
retaining 2 Mg2+, and water molecules within  5Å around the ligand, BPH-652.  We used the 
virtual screening workflow in Glide program [16], which docks and scores compounds in three 
difference stages: HTVS (high-throughput virtual screening)  SP (standard precision)  XP 
(extra precision), and each stage was set to filter out 90% of the input ligands.  We screened 
2,372 compounds from the Life Chemical anti-bacterial library [17] (which is thought to contain 
compounds that might have anti-bacterial activity) and 14,400 compounds from the Maybridge 
Hit Finder library [18].  Three hits (5-10) with CrtM activity from each library are shown in 
Figure 5.6.  What is of interest here is that each of these compounds is a carboxylic acid (green) 
attached either to a benzene ring or other hydrophobic group (in yellow), plus, in each case there 
is a far more distal aromatic feature (shown in grey).  We attempted crystallization of all 
compounds and obtained crystals that diffracted well for 8 (BPH-1183) (2.07Å) and 10 (BPH-
1162) (2.00Å).  Full crystallographic data and structure refinement details are given in Table 5.1.  
Electron density maps are shown in Figures 5.3C and D. 
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 We show in Figures 5.7A-D the structures of 8 (BPH-1183) and 10 (BPH-1162) bound to 
CrtM.  In both cases, what can immediately be seen are that the more distal, hydrophobic, 
diphenylmethane (8) and diphenylsulfide side-chains (10) bind to both the S1 as well as S2 
hydrophobic pockets, with in both cases one phenyl group being centered at ~C5 in the S2 FSPP 
sidechain position while the second phenyl group overlaps the position occupied by the end of 
the FSPP, in S1.  This is the same binding motif as found with BPH-702, a potent 
benzylbiphenyl phosphonosulfonate ([10], PDB 1D code 3ACY).  However, with 8 (BPH-1183), 
the carboxyl group binds via Arg in the polar group region in S2, Figure 5.7B, while in BPH-
1162, the carboxyl group binds to Mg2+A in S1, Figure 5.7C,D. Both inhibitors have good 
activity against CrtM with Ki ~ 300 nM, and >20 µM IC50 against human cancer cell lines.  
However, the initial screening hits are not active in S. aureus pigment assay (IC50 >100 µM). 
 Based on the preponderance of ortho-substituted benzoic acid in the HTS hits (3/4 
compounds having on average a CrtM Ki ~400 nM, we next carried out a similarity search in 
PubChem [19] to find other potential leads, using the model compound shown in Figure 5.8 as a 
template.  An interesting result was that the compound S-farnesyl-thiolobenzoic acid, Salirasib 
(11), was returned as a similar compound.  Salirasib blocks Ras signaling by binding to galectin 
[20] and is currently in clinical trials for lung, pancreatic, and hematological cancer, and since it 
is orally available, appeared an interesting possible lead.  We found Salirasib had a Ki = 113 nM 
in the CrtM enzyme assay, but cell activity was poor, IC50 = 75 µM.  We reasoned that a longer 
chain (geranylgeranyl) analog of 11, 12 (BPH-1088) might have better activity since it is know 
that geranylgeranyl diphosphate can bind to the S2 site [10], and in deed, 12 had a 28 nM Ki 
versus CrtM as well as a 4 µM IC50 in pigment inhibition.  We then produced 5 analogs, 13-17 
(Figure 5.8) based on 11 and the pharmacophore model (Figure 5.8) built upon four validated 
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screening hits (5, 6, 8, and 10).  Among them, 16 (BPH-1102) had a ~120 nM activity in pigment 
inhibition.  We attempted to crystallize (soaking as well as co-crystallization) each of 11-17 
bound to CrtM. In most cases, we found no ligand density, and protein-ligand mixtures failed to 
co-crystalize, but soaking 16 yielded crystals that diffracted to 2.0Å, although there was missing 
density in the benzoate region, due presumably to structure disorder.  We thus next made the Br-
analog of 16, 18 (BPH-1154), and one crystal, after soaking in the solution of Br-analog for 4 
hours, diffracted to 3.00Å (Table 5.1).  Although this is only moderate resolution, the electron 
density (Figure 5.3E) clearly indicates that the long alkyl chain binds to the S2 site, and is 
essentially superimposed on the S2 FSPP side-chain, while the benzyl (forming T-shape π-
stacking with Tyr 41) and bromobenzoate fragments bind in the S1 site, Figure 5.7E, F.  As with 
the diketo acids, all three carboxylate inhibitors (8, 10, 18) have polar group interactions with 
Mg2+ and/or Arg residues and extensive hydrophobic interactions that contribute to their activity. 
 
5.4   Materials and Methods 
X-Ray Crystallography  CrtM expression, purification, and inhibition assay were done as 
described previously [10, 12].  Native CrtM crystals (space group P3221) were grown by using 
the hanging-drop method by mixing equal amounts of reservoir with 0.2-1.0 M potassium 
sodium tartrate, at room temperature.  Inhibitor bound crystals were obtained by either soaking 
the native crystals with 1 mM ligand for 1-4 hours, or incubating protein-ligands (1 mM) 
mixtureat RT for 1-4 hours, then adding the reservoir solution.  All CrtM crystals belonged to the 
P3221 space group and had similar lattice parameters.  Diffraction data were collected in sector 
21 of APS, Argonne National Laboratory.  The data were indexed, integrated and scaled by using 
the HKL2000 package [21]. Structures were determined by molecular replacement with the 
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program Phaser [22], using apo CrtM (PDB ID 2ZCP minus ligands) as a template. Further 
model building, ligand preparation, and refinement employed Coot [23], ProDRG server [24], 
and Refmac in CCP4 [25, 26], respectively.  All Figures were prepared using PyMol [27]. 
 
5.5   Conclusions 
             Overall, results described above are of interest for several reasons.  First, we report the 
observation that diketo acids (tautomers of 2-hydroxyacrylates) act as inhibitors of the head-to-
head triterpene synthase CrtM, from S. aureus, a target for anti-virulence factor based 
therapeutics.  This result is of interest since it involves a rational approach to inhibitor discovery 
based on a proposed analogy between the CrtM and HIV-1 integrase active sites, which are both 
Asp-rich and bind Mg2+, and the observation that diketoacids inhibit HIV-1 integrase.  Second, 
we report that another class of HIV-1 integrase inhibitor analogs, dihydropyridine carboxylates, 
also inhibit CrtM and block pigment production, in cells, with in both cases the inhibitor head 
group binds to Mg2+ in the CrtM active site.  Third, we have used HTS to find other CrtM 
inhibitor leads.  Using in silico screening, we found several carboxylic acid inhibitors with potent 
activities against the CrtM.  In one case, the carboxylic acid group bound to Arg, in the other, to 
Mg2+.  Based on the HTS and similarity search results, we obtained several potent benzoic acid 
derivatives that blocked pigment formation in cells at ~100 nM levels.  While further work is 
required in order to progress these leads, and test them in vivo, the observation that phosphonate-
free CrtM inhibitors can be obtained is encouraging, since such compounds may have improved 
bioavailability, as recently noted in the context of farnesyl diphosphate synthase inhibitors by 
Jahnke et al. [28]. 
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5.6 Tables and Figures 
Table 5.1 Data collection and refinement statistics of CrtM-inhibitor complexes 
Crystal 
1 (CrtM-1034) 
(Soaking) 
(3P00 ) 
3 (CrtM-1112) 
(Soaking) 
(3PAI ) 
8 (CrtM-1183) 
 (Co-crystal) 
(3O68 ) 
10 (CrtM-1162) 
 (Co-crystal) 
(3O67) 
18 (CrtM-1154) 
(Soaking) 
(3O9Y ) 
Data collection 
Radiation source APS 21-ID-F APS 21-ID-G APS 21-ID-F APS 21-ID-F APS 21-ID-F 
Wavelength (Å) 0.97857 0.97857 0.97857 0.97857 0.97857 
Space group P3221 P3221 P3221 P3221 P3221 
a(Å) 80.712 80.194 80.229 80.246 80.999 
b(Å) 80.712 80.194 80.229 80.246 80.999 
c (Å) 90.864 91.333 91.820 92.196 90.737 
Resolution (Å)a 50.00-2.30 50.00-1.91 50.00-2.07 50.00-2.00 50.00-3.00 
 (2.34-2.30) (1.94-1.91) (2.11-2.07) (2.05-2.00) (3.05-3.00) 
No. of reflections 29147 (1422) 26704 (1132) 21465 (1044) 22438 (1294) 7190 (359) 
Completeness (%) 98.8 (95.4) 98.7 (87.0) 99.9 (100) 99.9 (100) 99.9 (99.4) 
Redundancy 3.2 (3.0) 5.5 (3.9) 12.6 (9.1) 11.3 (7.7) 10.4 (7.8) 
Rmerge (%) 8.3 (33.3) 7.2 (30.5) 8.3 (46.4)  7.0 (38.7) 8.5 (50.8) 
I/s(I) 18.6 (3.0) 39.5 (3.9) 40.5 (4.1) 41.5 (6.4) 38.2 (4.06) 
Refinement 
Resolution (Å)a 50.00-2.06 30.00-1.98 50.00-2.07 30.00-2.00 50.00-3.00 
No. of reflections 14844 (779) 23039 (1357) 20136 (1472) 22406 (1643) 6800 (460) 
Rwork (%) 19.9 (23.6) 20.2 (22.8) 18.7 (22.5) 18.9 (20.6) 20.8 (21.5) 
Rfree (%) 26.67 (25.6) 23.8 (29.5) 22.3 (25.0) 24.5 (30.7) 29.0 (37.2) 
Geometry deviations 
Bond lengths (Å) 0.005 0.007 0.023 0.024 0.013 
Bond angles (°) 0.62 1.01 1.789 1.731 1.372 
Mean B-values ( Å2) /  number of non-H atoms 
All refined atoms 33.2 / 2547 32.8 / 2590 31.4 / 2609 26.0 / 2592 55.0 / 2420 
Ligand atoms 53.3 / 55 43.6 / 21 55.2 / 31 43.7 / 28 71.1 / 27 
Mg ions 51.6 / 2 43.3 / 3 48.4 / 1 49.6 / 2 60.2 / 1 
Water molecules 36.4 / 123 35.2 / 178  36.9 / 176 32.5 / 172 - 
Ramachandran plot (%) 
Most favored 97.83 97.10 98.21 97.87 89.72 
Additionally allowed 1.81 2.50 1.08 1.77 7.8 
Generously allowed 0.36 0.40 0.72 0.35 2.48 
aValues in the perentesis from highest resolution shell. 
 
 
113 
Table 5.2 Toxicity (from 3 cancer cell lines) of compounds in this chapter. 
Compound MCF-7 cells (µM) NCI-H460 cells (µM) SF-268 cells (µM) Cancer average (µM) 
1 (BPH-1034) 131.2 237.8 350.1 239.7 
2 (BPH-1091) ND ND ND ND 
3 (BPH-1112) 4.9 2.3 3.9 3.7 
4 (BPH-1118) 53.7 96.7 104.2 84.9 
5 (BPH-945) 256 136 163 185 
6 (BPH-946) 35.0 29.4 30.9 31.8 
8 (BPH-1183) 15.7 13.6 30.1 19.8 
10 (BPH-1162) 100.3 127.1 102.0 109.8 
11 (BPH-939) 15.7 16.5 19.9 17.4 
12 (BPH-1088) 11.5 16.6 26.9 18.3 
13 (BPH-948) 41.2 43.4 41.2 41.9 
14 (BPH-1064) 82.7 137 70.8 96.8 
15 (BPH-1066) 20.3 12.5 13.3 15.4 
16 (BPH-1102) 16.5 17.4 12.9 15.6 
17 (BPH-1167) 7.5 9.5 11.8 9.6 
18 (BPH-1154) 36.7 33.9 52.5 41.0 
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Figure 5.1 Chemical structures of two metal chelating groups of (A) diketo acid and (B) 
dihydroquinoline, and the designed CrtM inhibitors derived from them. 
 
 
               ND: not determined. 
 
 
Figure 5.2  Crystal structure of BPH-1034 bound to CrtM. (A) Superposition of BPH-
1034+FMP with two FSPP molecules. (B) Superposition of BPH-1034 with BPH-652 (C) 
Interactions of BPH-1034 and FMP with the protein. 
 
 
 
 
40 
ND 
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Figure 5.3 Electron densities (2Fo-Fc, 1σ in grey, 2σ in red) of compounds in this chapter.  (A) 
BPH-1034 and FMP (B) BPH-1112 (C) BPH-1183 (D) BPH-1162 (E) BPH-1154. 
 
 
 
 
 
 
 
 
 
Figure 5.4  LC-MS result of farnesyl monophosphate (m/z 301.3). 
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Figure 5.5  Crystal structure of BPH-1112 bound to CrtM. (A) Superposition of BPH-1112 with 
two FSPP molecules showing BPH-1112 binds to the S2 site (B) Interactions of BPH-1112 with 
CrtM (C) LigPlot of BPH-1112 
 
 
 
 
 
 
 
Figure 5.6  Chemical structures of the hits from high-throughput computational screening 
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Figure 5.7 Crystal structures of BPH-1182, 1162, and 1164 bound to CrtM (A) Superimpose of 
BPH-1183 to two FSPP molecules (B) Residues of CrtM interacting with BPH-1183 (C) 
Superimpose of BPH-1162 with FSPP (D) Mg2+ ion and residues of CrtM interacting with BPH-
1183 (E) Superimpose of BPH-1154 with FSPP (F) Mg2+ ion and residues of CrtM interacting 
with BPH-1154. 
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Figure 5.8  Design of benzoate inhibitors based on computational screening hits and an orally 
active drug in Phase III clinical trial, FTS.  The corresponding enzyme and cell activities are 
shown below each compound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119 
5.7   References 
 
1. Research, N. and Council, Treating Infectious Diseases in a Microbial World: Report of 
Two Workshops on Novel Antibacterial Therapeutics. Washington, DC, 2006: p. 21-22. 
2. Fischbach, M.A. and C.T. Walsh, Antibiotics for emerging pathogens. Science, 2009. 
325(5944): p. 1089-93. 
3. Wang, R., et al., Identification of novel cytolytic peptides as key virulence determinants 
for community-associated MRSA. Nat Med, 2007. 13(12): p. 1510-4. 
4. Clatworthy, A.E., E. Pierson, and D.T. Hung, Targeting virulence: a new paradigm for 
antimicrobial therapy. Nat Chem Biol, 2007. 3(9): p. 541-8. 
5. Liu, G.Y., et al., Staphylococcus aureus golden pigment impairs neutrophil killing and 
promotes virulence through its antioxidant activity. J Exp Med, 2005. 202(2): p. 209-15. 
6. Pelz, A., et al., Structure and biosynthesis of staphyloxanthin from Staphylococcus 
aureus. J Biol Chem, 2005. 280(37): p. 32493-8. 
7. Liu, C.I., et al., A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus 
virulence. Science, 2008. 319(5868): p. 1391-4. 
8. Magnin, D.R., et al., alpha-Phosphonosulfonic acids: potent and selective inhibitors of 
squalene synthase. J Med Chem, 1996. 39(3): p. 657-60. 
9. Flint, O.P., et al., Inhibition of cholesterol synthesis by squalene synthase inhibitors does 
not induce myotoxicity in vitro. Toxicol Appl Pharmacol, 1997. 145(1): p. 91-8. 
10. Lin, F.Y., et al., Mechanism of action and inhibition of dehydrosqualene synthase. Proc 
Natl Acad Sci U S A, 2010. 
 
120 
11. Grobler, J.A., et al., Diketo acid inhibitor mechanism and HIV-1 integrase: implications 
for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U 
S A, 2002. 99(10): p. 6661-6. 
12. Song, Y., et al., Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene 
synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem, 2009. 
52(4): p. 976-88. 
13. Sechi, M., et al., Design and synthesis of novel dihydroquinoline-3-carboxylic acids as 
HIV-1 integrase inhibitors. Bioorg Med Chem, 2009. 17(7): p. 2925-35. 
14. Friesner, R.A., et al., Glide: a new approach for rapid, accurate docking and scoring. 1. 
Method and assessment of docking accuracy. J Med Chem, 2004. 47(7): p. 1739-49. 
15. Aaron, J.A. and D.W. Christianson, Trinuclear metal clusters in catalysis by terpenoid 
synthases. Pure and Applied Chemistry, 2010. 82(8): p. 1585-1597. 
16. Halgren, T.A., et al., Glide: a new approach for rapid, accurate docking and scoring. 2. 
Enrichment factors in database screening. J Med Chem, 2004. 47(7): p. 1750-9. 
17. Life Chemical, Inc.; Available from: http://www.lifechemicals.com/. 
18. Maybridge, Inc.; Available from: http://www.maybridge.com/. 
19. Wang, Y., et al., PubChem: a public information system for analyzing bioactivities of 
small molecules. Nucleic Acids Res, 2009. 37: p. W623-33. 
20. Paz, A., et al., Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage 
and cell transformation. Oncogene, 2001. 20(51): p. 7486-93. 
21. Minor, W., et al., HKL-3000: the integration of data reduction and structure solution--
from diffraction images to an initial model in minutes. Acta Crystallogr D Biol 
Crystallogr, 2006. 62: p. 859-66. 
 
121 
22. McCoy, A.J., et al., Phaser crystallographic software. J Appl Crystallogr, 2007. 40: p. 
658-674. 
23. Emsley, P. and K. Cowtan, Coot: model-building tools for molecular graphics. Acta 
Crystallogr D Biol Crystallogr, 2004. 60: p. 2126-32. 
24. Schuttelkopf, A.W. and D.M. van Aalten, PRODRG: a tool for high-throughput 
crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr, 2004. 
60: p. 1355-63. 
25. Murshudov, G.N., A.A. Vagin, and E.J. Dodson, Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr, 
1997. 53(Pt 3): p. 240-55. 
26. Potterton, E., et al., A graphical user interface to the CCP4 program suite. Acta 
Crystallogr D Biol Crystallogr, 2003. 59: p. 1131-7. 
27. DeLano, W.L., The PyMOL Molecular Graphics System, 2008, DeLano Scientific  LLC. 
28. Jahnke, W., et al., Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-
based discovery. Nat Chem Biol, 2010. 6(9): p. 660-6. 
 
 
